"","pmid","doi","title","abstract","year","month","day","jabbrv","journal","keywords","lastname","firstname","address","email"
"1","33129610","10.1016/j.vaccine.2020.10.056","India's cost-effective COVID-19 vaccine development initiatives.",NA,"2020","12","11","Vaccine","Vaccine","Animals; COVID-19 Vaccines; Clinical Trials as Topic; Costs and Cost Analysis; Drug Development; Drug Evaluation, Preclinical; Humans; India; International Cooperation","Chakraborty","Chiranjib","Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India. Electronic address: drchiranjib@yahoo","drchiranjib@yahoo.com"
"2","33127862","10.1128/mBio.02707-20","Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.","We sequenced the genomes of 5,085 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains causing two coronavirus disease 2019 (COVID-19) disease waves in metropolitan Houston, TX, an ethnically diverse region with 7 million residents. The genomes were from viruses recovered in the earliest recognized phase of the pandemic in Houston and from viruses recovered in an ongoing massive second wave of infections. The virus was originally introduced into Houston many times independently. ","2020","11","18","mBio","mBio","COVID-19; COVID-19 disease; SARS-CoV-2; evolution; genome sequencing; molecular population genomics; Amino Acid Sequence; Amino Acid Substitution; Antibodies, Neutralizing; Base Sequence; Betacoronavirus; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; Genome, Viral; Genotype; Humans; Machine Learning; Models, Molecular; Molecular Diagnostic Techniques; Pandemics; Phylogeny; Pneumonia, Viral; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sequence Analysis, Protein; Spike Glycoprotein, Coronavirus; Texas; Viral Nonstructural Proteins","Long","S Wesley","Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA",NA
"3","33125926","10.1016/S0140-6736(20)32259-5","Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.",NA,"2020","11","30","Lancet","Lancet (London, England)","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Confidentiality; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Krause","Philip R","Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA",NA
"4","33125914","10.1016/S1473-3099(20)30773-8","What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.","The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused more than 1 million deaths in the first 6 months of the pandemic and huge economic and social upheaval internationally. An efficacious vaccine is essential to prevent further morbidity and mortality. Although some countries might deploy COVID-19 vaccines on the strength of safety and immunogenicity data alone, the goal of vaccine development is to gain direct evidence of vaccine efficacy in protecting","2021","02","15","Lancet Infect Dis","The Lancet. Infectious diseases","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Immunogenicity, Vaccine; Outcome Assessment, Health Care; Research Design; SARS-CoV-2; Treatment Outcome; Vaccination","Hodgson","Susanne H","The Jenner Institute, University of Oxford, Oxford, UK. Electronic address: susanne.hodgson@ndm.ox.ac","susanne.hodgson@ndm.ox.ac.uk"
"5","33123165","10.3389/fimmu.2020.579250","Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.","There are currently around 200 SARS-CoV-2 candidate vaccines in preclinical and clinical trials throughout the world. The various candidates employ a range of vaccine strategies including some novel approaches. Currently, the goal is to prove that they are safe and immunogenic in humans (phase 1/2 studies) with several now advancing into phase 2 and 3 trials to demonstrate efficacy and gather comprehensive data on safety. It is highly likely that many vaccines will be shown to stimulate antibody","2020","11","09","Front Immunol","Frontiers in immunology","Coalition for Epidemic Preparedness Innovations (CEPI); adverse events of special interest (AESI); antibody dependent enhancement (ADE); bacillus Calmette-Gu..rin (BCG); cell mediated immunity; innate immunity; neutralizing antibodies; spike protein; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes, Cytotoxic; Vaccination; Viral Vaccines; Young Adult","Flanagan","Katie L","Department of Infectious Diseases, Launceston General Hospital, Launceston, TAS, Australia",NA
"6","33120812","10.1097/MD.0000000000022840","Analysis of the WHO ICTRP for novel coronavirus clinical trial registrations.","Up-to-date information on the current progress made in the research and development to control the global COVID-19 pandemic is important. The study aimed to analyze the clinical trial characteristics and vaccine development progress of the new Coronavirus Disease 2019 (COVID-19) registered with the World Health Organization International Clinical Trial Registry Platform (WHO ICTRP).A comprehensive search of COVID-19 clinical trials since the establishment of the ICTRP to June 11, 2020, was condu","2020","11","09","Medicine (Baltimore)","Medicine","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Quality Improvement; Registries; Research Design; SARS-CoV-2; Viral Vaccines; World Health Organization","Song","Gao","Department of Pharmacy, Pu'er People's Hospital",NA
"7","33119725","10.1371/journal.ppat.1008969","&quot;Trained immunity&quot; from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes.","Protective variables for Coronavirus Disease 2019 (COVID-19) are unknown. &quot;Trained immunity&quot; of the populace as a result of Bacille Calmette-Gu..rin (BCG) vaccination policy implementation and coverage had been suggested to be one of the factors responsible for the differential impact of COVID-19 on different countries. Several trials are underway to evaluate the potential protective role of BCG vaccination in COVID-19. However, the lack of clarity on the use of appropriate controls co","2020","11","05","PLoS Pathog","PLoS pathogens","BCG Vaccine; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Immunity, Cellular; Mycobacterium; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vaccination","Singh","Samer","Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India",NA
"8","33119547","10.1172/JCI140491","Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection.","SARS-CoV-2 causes a wide spectrum of clinical manifestations and significant mortality. Studies investigating underlying immune characteristics are needed to understand disease pathogenesis and inform vaccine design. In this study, we examined immune cell subsets in hospitalized and nonhospitalized individuals. In hospitalized patients, many adaptive and innate immune cells were decreased in frequency compared with those of healthy and convalescent individuals, with the exception of an increase ","2021","01","15","J Clin Invest","The Journal of clinical investigation","COVID-19; Cellular immune response; Immunology; Adult; Aged; Aged, 80 and over; Antigens, Differentiation; B-Lymphocytes; COVID-19; Female; Humans; Lymphocyte Activation; Male; Middle Aged; SARS-CoV-2; T-Lymphocytes","Files","Jacob K","Division of Infectious Diseases, Department of Medicine, School of Medicine",NA
"9","33115909","10.1136/postgradmedj-2020-138903","Will vaccination refusal prolong the war on SARS-CoV-2?","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that appeared in Wuhan, China in January 2020 and caused a global pandemic drastically changing everyday life. Currently, there are vaccine candidates in clinical trials and development, so it is only a matter of time before one is authorised for human use. We collected public opinion survey results about attitudes towards SARS-CoV-2 vaccination conducted in 2020 in 26 European countries. The pooled surveys were ","2021","02","26","Postgrad Med J","Postgraduate medical journal","Clinical pharmacology; Infection control; Infectious diseases; Public health; Attitude to Health; COVID-19; COVID-19 Vaccines; Europe; Health Education; Humans; Immunity, Herd; Public Opinion; SARS-CoV-2; Surveys and Questionnaires; Vaccination Refusal","Marcec","Robert","University of Zagreb School of Medicine, Zagreb, Croatia",NA
"11","33113270","10.1111/ijcp.13795","Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease.","Patient comprehension is a critical part of meeting medical ethics standards of informed consent in study designs. The aim of the study was to determine if sufficient literature exists to require clinicians to disclose the specific risk that COVID-19 vaccines could worsen disease upon exposure to challenge or circulating virus. Published literature was reviewed to identify preclinical and clinical evidence that COVID-19 vaccines could worsen disease upon exposure to challenge or circulating viru","2021","01","16","Int J Clin Pract","International journal of clinical practice",NA,"Cardozo","Timothy","Department of Biochemistry and Molecular Pharmacology, NYU Langone Health, New York, NY, USA",NA
"12","33110944","10.12688/wellcomeopenres.15936.1","A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam.","Background: COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent COVID-19 or therapeutic agent to treat COVID-19. This clinical trial is designed to evaluate chloroquine as a potential therapeutic for the treatment of hospitalised people with COVID-19. We hypothesise that chloroquine slows viral replication in patients with COVID-19, attenuating the infection, and resulting in ","2020","10","29","Wellcome Open Res","Wellcome open research","COVID-19; Chloroquine; Randomised Clinical Trial; SARS-CoV-2; Vietnam; coronaviruses","Kestelyn","Evelyne","Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam",NA
"13","33110933","10.1016/j.dib.2020.106445","Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients.","The COVID-19 outbreak is now one of the most critical crises to manage for most of national healthcare systems in the world. The situation is complicated by the absence of vaccines and authorized pharmacological treatments, except for remdesivir. In this context, many medicaments, including different Ebola and HIV antivirals, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Authorized medicaments manipulation is sometimes necessary because they are not a","2021","02","17","Data Brief","Data in brief","COVID-19; Lopinavir; Medicament manipulation; Nasogastric tube; Osmolarity; Particle size distribution; Ritonavir","Zanon","D","Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy",NA
"14","33106170","10.1186/s13063-020-04822-0","BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.","The BCG vaccine, widely used in Brazil in new-borns, induces adjuvant protection for several diseases, including childhood virus infections. BCG activates monocytes and innate memory NK cells which are crucial for the antiviral immune response. Therefore, strategies to prevent COVID-19 in health workers (HW) should be carried out to prevent them becoming unwell so that they can continue to work during the pandemic. The hypothesis is that BCG will improve the innate immune response and prevent sy","2020","11","02","Trials","Trials","BCG revaccination; COVID-19; NK; Randomised controlled trial; cross-protection; health workers; innate immune response; macrophages; protocol; BCG Vaccine; Betacoronavirus; Brazil; COVID-19; Case-Control Studies; Coronavirus Infections; Cross Protection; Follow-Up Studies; Health Personnel; Hospitalization; Humans; Immunity, Innate; Immunization, Secondary; Immunoglobulin G; Immunoglobulin M; Incidence; Injections, Intradermal; Killer Cells, Natural; Pandemics; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Safety; Treatment Outcome","Junqueira-Kipnis","Ana Paula","Institute of Tropical Pathology and Public Health, Federal University of Goi..s, Goi..nia, Goi..s, Brazil. ana_kipnis@ufg","kipnis@ufg.br"
"15","33104216","10.1093/cid/ciaa1653","FDA Emergency Use Authorization: Glass Half Empty?","Recently, the Food and Drug Administration (FDA) issued emergency use authorization (EUA) of convalescent plasma (CP) for the treatment of COVID-19 hospitalized patients based on a non-peer reviewed open label observational study. Issuance of an EUA without a proven randomized control trial (RCT) sets a dangerous precedent since the premature action drives health care providers and patients away from RCTs that are essential for determining the efficacy and safety of CP. More caution should have ","2020","11","17","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","Emergency use authorization; convalescent plasma; public trust; randomized control trial","Guharoy","Roy","Pharmacy, Baptist Health and Infectious Diseases, University of Massachusetts Medical School",NA
"16","33103108","10.1016/j.gloepi.2020.100036","Impact assessment of full and partial stay-at-home orders, face mask usage, and contact tracing: An agent-based simulation study of COVID-19 for an urban region.","Social intervention strategies to mitigate COVID-19 are examined using an agent-based simulation model. Outbreak in a large urban region, Miami-Dade County, Florida, USA is used as a case study. Results are intended to serve as a planning guide for decision makers. The simulation model mimics daily social mixing behavior of the susceptible and infected generating the spread. Data representing demographics of the region, virus epidemiology, and social interventions shapes model behavior. Results ","2021","01","11","Glob Epidemiol","Global epidemiology","Agent-based simulation model; COVID-19; Contact tracing; Face mask; Intervention strategies; SARS-CoV-2","Tatapudi","Hanisha","Department of Industrial and Management System Engineering, University of South Florida, Tampa, FL, USA",NA
"17","33101792","10.7759/cureus.10530","Bioethical Implications in Vaccine Development, a COVID-19 Challenge.","Introduction In the last 18 years, on three occasions, coronavirus has represented a challenge for global health. Between 2002 and 2003 with Severe Acute Respiratory Syndrome, in 2012 with Middle East Respiratory Syndrome, and since the end of 2019 with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease 2019 (COVID-19) pandemic, which has challenged health care models and the way of doing research, placing bioethics at the center of discussion... Methods","2020","10","28","Cureus","Cureus","bioethics; clinical trial; covid-19; social value; vaccine","Ospina Henao","Sebasti..n","Instituto de Investigaci..n en Ciencias M..dicas, Universidad de Ciencias M..dicas, San Jos.., CRI",NA
"18","33100195","10.2174/1381612826666201023143956","COVID-19 Vaccines on Clinical Trials and their Mode of Action for Immunity against the Virus.","For nearly two decades, coronaviruses have caused many health and economic problems, while no effective commercial vaccine has yet been developed. It is worth mentioning that despite some mutations and recombination in SARS-CoV-2, its genotype is very close to the original strain from Wuhan, China. Therefore, the development of an effective vaccine would be promising. It might be hypothesized that BCG vaccination is performed in high-risk populations before the commercialization of an effective ","2020","10","26","Curr Pharm Des","Current pharmaceutical design","ADE; COVID-19; SARS-CoV-2; clinical.; coronavirus; immune enhancement; spike; vaccine","Tavakol","Shima","Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran. Iran",NA
"19","33098441","10.1007/s00038-020-01494-0","Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland.","Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and subgroups are key for evaluating mitigation and vaccination policies and for understanding the spread of the disease both on the national level and for comparison with the international community. Corona Immunitas is a research program of coordinated, population-based, seroprevalence studies implemented by Swiss School of Public Health (SSPH+). Over 28,340 participants, randomly selected and age-str","2020","12","16","Int J Public Health","International journal of public health","Hygiene practices; Longitudinal; Prevalence; SARS-CoV-2; Serosurvey; Socioeconomic differences; Adolescent; Adult; Aged; Antibodies, Viral; Betacoronavirus; COVID-19; Child; Ethnic Groups; Humans; Middle Aged; Pandemics; Pneumonia, Viral; Research Design; SARS-CoV-2; Seroepidemiologic Studies; Switzerland; Young Adult","West","Erin A","Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, 8001, Zurich, Switzerland",NA
"20","33097472","10.1126/sciadv.abc7112","Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.","To affect the COVID-19 pandemic, lifesaving antiviral therapies must be identified. The number of clinical trials that can be performed is limited. We developed mathematical models to project multiple therapeutic approaches. Our models recapitulate off-treatment viral dynamics and predict a three-phase immune response. Simulated treatment with remdesivir, selinexor, neutralizing antibodies, or cellular immunotherapy demonstrates that rapid viral elimination is possible if in vivo potency is suff","2020","12","11","Sci Adv","Science advances","Adenosine Monophosphate; Adoptive Transfer; Alanine; Antibodies, Viral; Antiviral Agents; Broadly Neutralizing Antibodies; COVID-19; Cell- and Tissue-Based Therapy; Humans; Hydrazines; Killer Cells, Natural; Models, Theoretical; SARS-CoV-2; Time Factors; Treatment Outcome; Triazoles; Viral Load; Virus Shedding","Goyal","Ashish","Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA",NA
"21","33096260","10.1016/j.accpm.2020.10.006","Vaccines against COVID-19.",NA,"2020","12","23","Anaesth Crit Care Pain Med","Anaesthesia, critical care &amp; pain medicine","Adenovirus; Neutralising antibodies; mRNA vaccine; Adenoviridae; Antibodies, Neutralizing; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Development; Humans; RNA, Messenger; SARS-CoV-2; Vaccines, Inactivated","Locht","Camille","Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France. Electronic address: camille.locht@pasteur-lille",NA
"22","33094258","10.7861/fhj.2020-0079","Remodelling elective hospital services in the COVID-19 era - designing the new normal.","The provision of elective clinical services has decreased during the initial phase of the coronavirus disease 2019 (COVID-19) pandemic to enable hospitals to focus on acute illness. Any end to the pandemic through widespread vaccination, effective treatment or development of herd immunity may be years away. Until then, hospitals will need to resume treating other diseases while also attempting to eradicate transmission of COVID-19 within the healthcare setting. In this article we suggest six maj","2020","10","24","Future Healthc J","Future healthcare journal","COVID-19; Healthcare system design; modernising healthcare","King","Lamin A","Dorset County Hospital, Dorchester, UK",NA
"23","33093087","10.1126/science.370.6515.389","First vaccine may stymie hunt for better ones.",NA,"2020","12","18","Science","Science (New York, N.Y.)","COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Humans; Pandemics; Russia; United States; United States Food and Drug Administration","Cohen","Jon",NA,NA
"24","33093069","10.1101/gr.266676.120","Sequencing identifies multiple early introductions of SARS-CoV-2 to the New York City region.","Effective public response to a pandemic relies upon accurate measurement of the extent and dynamics of an outbreak. Viral genome sequencing has emerged as a powerful approach to link seemingly unrelated cases, and large-scale sequencing surveillance can inform on critical epidemiological parameters. Here, we report the analysis of 864 SARS-CoV-2 sequences from cases in the New York City metropolitan area during the COVID-19 outbreak in spring 2020. The majority of cases had no recent travel hist","2020","12","14","Genome Res","Genome research","COVID-19; Female; Genome, Viral; Humans; Male; New York City; Pandemics; Phylogeny; SARS-CoV-2; Whole Genome Sequencing","Maurano","Matthew T","Institute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, USA",NA
"25","33093065","10.1136/bmj.m4042","Covid-19: Vaccine trials need more transparency to enable scrutiny and earn public trust, say experts.",NA,"2020","11","05","BMJ","BMJ (Clinical research ed.)","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Disclosure; Humans; Information Dissemination; Pandemics; Pneumonia, Viral; SARS-CoV-2; Safety; Trust; Viral Vaccines","Mahase","Elisabeth","The BMJ",NA
"26","33090877","10.7326/M20-6169","Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.","Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will soon enter large-scale, phase 3, placebo-controlled randomized clinical trials. To facilitate harmonized evaluation and comparison of the efficacy of these vaccines, a general set of clinical endpoints is proposed, along with considerations to guide the selection of the primary endpoints on the basis of clinical and stati","2021","02","24","Ann Intern Med","Annals of internal medicine","Asymptomatic Infections; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; Randomized Controlled Trials as Topic; SARS-CoV-2; Severity of Illness Index","Mehrotra","Devan V","Biostatistics and Research Decision Sciences, Merck &amp",NA
"27","33090030","10.1089/hs.2020.0038","Disinformation and Epidemics: Anticipating the Next Phase of Biowarfare.","While biological warfare has classically been considered a threat requiring the presence of a distinct biological agent, we argue that in light of the rise of state-sponsored online disinformation campaigns we are approaching a fifth phase of biowarfare with a &quot;cyber-bio&quot; framing. By examining the rise of measles cases following disinformation campaigns connected to the US 2016 presidential elections, the rise of disinformation in the current novel coronavirus disease 2019 pandemic, an","2021","02","26","Health Secur","Health security","Biowarfare; Disinformation; Epidemics; Infectious diseases; Infodemics; Public health preparedness/response; Anti-Vaccination Movement; Biological Warfare; COVID-19; Communication; Epidemics; Hemorrhagic Fever, Ebola; Humans; Information Dissemination; Measles; Politics; Social Media","Bernard","Rose","Rose Bernard, MA, and Gemma Bowsher, MBBS, are Research Associates",NA
"28","33087460","10.1126/science.abe5938","Understanding COVID-19 vaccine efficacy.",NA,"2020","11","24","Science","Science (New York, N.Y.)","Age Factors; Betacoronavirus; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Vaccination; Viral Load; Viral Vaccines; Virus Shedding","Lipsitch","Marc","Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. mlipsitc@hsph.harvard.edu nataliedean@ufl","mlipsitc@hsph.harvard.edu"
"29","33087452","10.1136/bmjebm-2020-111507","Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?","In the current era of the COVID-19 pandemic, the world has never been more interested in the process of vaccine development. While researchers across the globe race to find an effective yet safe vaccine to protect populations from the newly emergent SARS-CoV-2 virus, more than one-third of the world has been subjected to either full or partial lockdown measures. With communities having felt the burden of prolonged isolation, finding a safe and efficacious vaccine will yield direct beneficial eff","2020","10","22","BMJ Evid Based Med","BMJ evidence-based medicine","public health; vaccination; vaccine-preventable diseases","Dhanda","Sandeep","Drug Safety Research Unit, Southampton, Hampshire, UK sandeep.dhanda@dsru","sandeep.dhanda@dsru.org"
"30","33087398","10.1136/bmj.m4037","Will covid-19 vaccines save lives? Current trials aren't designed to tell us.",NA,"2020","10","23","BMJ","BMJ (Clinical research ed.)",NA,"Doshi","Peter","The BMJ",NA
"31","33087395","10.1136/bmj.m4058","Covid-19 vaccine trial protocols released.",NA,"2020","10","26","BMJ","BMJ (Clinical research ed.)","Access to Information; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Protocols; Coronavirus Infections; Drug Development; Humans; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; SARS-CoV-2; Viral Vaccines","Doshi","Peter","The BMJ",NA
"32","33085884","10.1056/NEJMp2025955","Covid-19 Vaccine Trials and Incarcerated People - The Ethics of Inclusion.",NA,"2020","11","16","N Engl J Med","The New England journal of medicine","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Prisoners; Research Subjects; SARS-CoV-2; Viral Vaccines","Strassle","Camila","From the Department of Bioethics, National Institutes of Health, Bethesda, MD",NA
"33","33084153","10.1111/risa.13614","A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.","COVID-19 led to a recent high-profile proposal to reintroduce oral poliovirus vaccine (OPV) in the United States (U.S.), initially in clinical trials, but potentially for widespread and repeated use. We explore logistical challenges related to U.S. OPV administration in 2020, review the literature related to nonspecific effects of OPV to induce innate immunity, and model the health and economic implications of the proposal. The costs of reintroducing a single OPV dose to 331 million Americans wo","2021","03","01","Risk Anal","Risk analysis : an official publication of the Society for Risk Analysis","COVID-19; health economics; oral poliovirus vaccine; polio; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Disease Eradication; Disease Outbreaks; Economics, Medical; Female; Global Health; Health Care Costs; Humans; Male; Poliomyelitis; Poliovirus Vaccine, Oral; Risk Management; United States; Vaccination","Thompson","Kimberly M","Kid Risk, Inc., Orlando, Florida, 32819, USA",NA
"34","33083500","10.1007/s13337-020-00633-8","2019-nCoV: a worldwide concern and facts.","A recent outbreak of endemic disease speeded by a virus whose genome is similar to that of SARS and MERS which outbreak in 2002 and 2012 respectively. All these are zoonotic infection which means these has transmitted from animal to human. Another similarity amongst these infections is that bat is supposed to be primary reservoir for these viruses. 2019-nCoV was reported by WHO on 31 December 2020 which is spreading with alarming rate. WHO has considered this infection as pandemic which means th","2020","10","22","Virusdisease","Virusdisease","2019-nCoV; Epidemic; Pandemic; Reproduction number; Zoonotic disease","Sharma","Rajani","Amity Institute of Biotechnology, Amity University Jharkhand, Niwaranpur, Ranchi, 834002 India",NA
"35","33083026","10.1038/s41541-020-00243-x","Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.","Development of effective preventative interventions against SARS-CoV-2, the etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS-CoV-2 is a key target for prophylactic measures as it is critical for the viral replication cycle and the primary target of neutralizing antibodies. We evaluated design elements previously shown for other coronavirus S protein-based vaccines to be successful, e.g., prefusion-stabilizing substitutions and heterologous signal peptid","2020","10","22","NPJ Vaccines","NPJ vaccines","SARS-CoV-2; Vaccines; Viral infection","Bos","Rinke","Janssen Vaccines &amp",NA
"36","33082599","10.1016/j.molstruc.2020.129459","Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect.","COVID-19, the pandemic disease recently discovered in Wuhan (China), severely spread and affected both social and economic activity all over the world. Attempts to find an effective vaccine are challenging, time-consuming though interminable. Hence, re-proposing effective drugs is reliable and effective alternative. Taking into account the genome similarity of COVID-19 with SARS-CoV, drugs with safety profiles could be fast solution. Clinical trials encouraged the use of Chloroquine and Hydroxyc","2021","02","06","J Mol Struct","Journal of molecular structure","COVID-19; Chloroquine; DFT calculations; Hydroxychloroquine; Sialic acid","Altalhi","Tariq A","Department of Chemistry, Collage of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia",NA
"37","33082550","10.1038/d41586-020-02821-4","Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials.",NA,"2020","11","02","Nature","Nature","Diseases; SARS-CoV-2; Vaccines; Adolescent; Adult; Aging; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Healthy Volunteers; Human Experimentation; Humans; Informed Consent; Pandemics; Patient Safety; Pneumonia, Viral; Risk Assessment; SARS-CoV-2; Uncertainty; United Kingdom; Viral Vaccines; Young Adult","Callaway","Ewen",NA,NA
"38","33082543","10.1038/d41586-020-02946-6","How obesity could create problems for a COVID vaccine.",NA,"2020","10","26","Nature","Nature","Immunology; Medical research; SARS-CoV-2; Adipose Tissue; Angiotensin-Converting Enzyme 2; Body Mass Index; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Critical Care; Humans; Obesity; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Viral Vaccines; World Health Organization","Ledford","Heidi",NA,NA
"39","33082093","10.1016/j.jcyt.2020.09.005","Temporary derogation from European environmental legislation for clinical trials of genetically modified organisms for coronavirus disease 2019.","Attempts to streamline environmental procedures for those products containing or consisting of genetically modified organisms (GMOs) among the European Union (EU) Member States are ongoing but still need to be further developed. These procedures can be complex, resource-intensive and time-consuming. Some candidate vaccines currently under development for COVID-19 include genetically modified viruses, which may be considered GMOs. Given the public health emergency caused by the COVID-19 outbreak,","2021","01","19","Cytotherapy","Cytotherapy","European Union; environmental monitoring; environmental policy; genetically modified organisms; risk assessment; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Europe; European Union; Humans; Organisms, Genetically Modified; Pandemics; Risk Assessment; SARS-CoV-2","Iglesias-Lopez","Carolina","Department of Pharmacology, Therapeutics and Toxicology, Universitat Aut..noma de Barcelona, Cerdanyola del Vall..s, Spain. Electronic address: carolina.iglesias.lopez.uab@gmail","carolina.iglesias.lopez.uab@gmail.com"
"40","33080068","10.1002/eji.202048915","Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients.","The characterization of cell-mediated and humoral adaptive immune responses to SARS-CoV-2 is fundamental to understand COVID-19 progression and the development of immunological memory to the virus. In this study, we detected T-cells reactive to SARS-CoV-2 proteins M, S, and N, as well as serum virus-specific IgM, IgA, IgG, in nearly all SARS-CoV-2 infected individuals, but not in healthy donors. Virus-reactive T cells exhibited signs of in vivo activation, as suggested by the surface expression ","2020","12","21","Eur J Immunol","European journal of immunology","Antibodies; Cellular immunology; Infectious diseases; Memory cells; Virology; Adult; Antibodies, Viral; COVID-19; Carrier State; Female; Humans; Immunity, Humoral; Programmed Cell Death 1 Receptor; Receptors, Immunologic; SARS-CoV-2; T-Lymphocytes; Viral Proteins","Mazzoni","Alessio","Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy",NA
"41","33079612","10.1080/21645515.2020.1831859","The Missing Link in the Covid-19 Vaccine Race.","Operation Warp Speed and global vaccine research efforts have succeeded in rapidly launching three vaccine candidates for coronavirus disease 2019 (COVID-19) into Phase III clinical trials. A recent letter from Centers for Disease Control and Prevention (CDC) Director Redfield underscored the possibility of &quot;large-scale&quot; distribution of a coronavirus vaccine as early as November 1, 2020. However, recent polling reveals that the majority of Americans remain skeptical of both the safety ","2020","10","20","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","Covid-19; immunization campaign; vaccine; vaccine hesitancy; vaccine marketing","Zizzo","John","University of Miami Miller School of Medicine , Miami, FL, USA",NA
"42","33078736","10.4103/ijp.IJP_709_20","The narrow road to a COVID-19 vaccine.",NA,"2020","10","29","Indian J Pharmacol","Indian journal of pharmacology","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Viral Vaccines","Maurya","Shesh Prakash","Department of Microbiology and Infectious Diseases, National HIV Reference Laboratory and Immunology Laboratory, All India Institute of Medical Sciences, New Delhi, India",NA
"43","33077943","10.1038/d41586-020-02926-w","All eyes on a hurdle race for a SARS-CoV-2 vaccine.",NA,"2020","10","23","Nature","Nature","Immunology; Medical research; SARS-CoV-2; Vaccines; Adolescent; Adult; B-Lymphocytes; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2; T-Lymphocytes; United States; United States Food and Drug Administration; Vaccination; Viral Vaccines; Young Adult","Gaebler","Christian",NA,NA
"44","33077678","10.1126/scitranslmed.abe0948","Prospects for a safe COVID-19 vaccine.","Rapid development of an efficacious vaccine against the viral pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infe","2020","11","18","Sci Transl Med","Science translational medicine","Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Disease Models, Animal; Drug Development; Humans; Pandemics; Pneumonia, Viral; Vaccination; Viral Vaccines","Haynes","Barton F","Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. barton.haynes@duke","barton.haynes@duke.edu"
"45","33074704","10.7326/M20-6841","COVID-19 Vaccine: What Physicians Need to Know.",NA,"2020","11","30","Ann Intern Med","Annals of internal medicine","Betacoronavirus; COVID-19 Vaccines; Clinical Trials as Topic; Congresses as Topic; Coronavirus Infections; Evidence-Based Medicine; Humans; SARS-CoV-2; United States; United States Food and Drug Administration; Viral Vaccines","Laine","Christine","Editor in Chief, Annals of Internal Medicine (C",NA
"46","33072781","10.3389/fmed.2020.552991","The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak.","The coronavirus disease 19 (COVID-19) pandemic poses a serious threat to the sustainability of healthcare systems and is currently having a significant effect on living conditions worldwide. No therapeutic agent has yet proven to be effective for the treatment of COVID-19. The management of this disease currently relies on supportive care and the off-label and compassionate use of antivirals and immunomodulators. Nevertheless, there has been a great worldwide effort to progress research and test","2020","10","20","Front Med (Lausanne)","Frontiers in medicine","COVID-19; SARS-CoV-2; antivirals; clinical trials; drug development; immunomodulators; research protocols","Canevelli","Marco","National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy",NA
"47","33072111","10.3389/fimmu.2020.570063","Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment.","Coronavirus disease 2019 (COVID-19) is a pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most infected people have mild or moderate symptoms and recover without the need for extensive treatment. However, for seriously ill patients, no specific treatments are currently available. Convalescent plasma therapy (CPT), a passive immunotherapy, involves infusing plasma from recovered people into actively infected people, and is thought to be a specific intervention ","2020","10","26","Front Immunol","Frontiers in immunology","antibody; convalescent plasma therapy; coronavirus disease 2019; immunotherapy; severe acute respiratory syndrome coronavirus-2; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Immunization, Passive; Pandemics; Plasma; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2","Ouyang","Jing","Infectious Diseases and Immunity in Global Health Program, Research Institute, McGill University Health Centre, Montr..al, QC, Canada",NA
"48","33070079","10.1016/j.ejmech.2020.112862","Primed for global coronavirus pandemic: Emerging research and clinical outcome.","The global effort to combat and contain the coronavirus disease 2019 (COVID-19) caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now proceeding on a war footing. The world was slow to react to the developing crisis, but once the contours of the impending calamity became evident, the different state and non-state actors have raced to put their act together. The COVID-19 pandemic has blatantly exposed the shortcomings of our healthcare system and th","2020","12","30","Eur J Med Chem","European journal of medicinal chemistry","Antiviral drugs; COVID-19; Clinical trials; Drug repurposing; Monoclonal antibodies; SARS-CoV-2; Small molecule drugs; Vaccines; Antiviral Agents; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Repositioning; Humans; Pandemics; SARS-CoV-2","Ahamad","Shakir","Department of Chemistry, Aligarh Muslim University, Aligarh, 202002, UP, India",NA
"49","33069443","10.1016/j.vaccine.2020.10.012","COVID-19 vaccine trials: Duty of care and standard of prevention considerations.",NA,"2020","11","12","Vaccine","Vaccine","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Approval; Humans; International Cooperation; Pandemics; Patient Safety; Personal Protective Equipment; Pneumonia, Viral; Practice Guidelines as Topic; Risk Assessment; SARS-CoV-2; Viral Vaccines","Singh","Jerome Amir","CAPRISA, University of KwaZulu-Natal, Durban, South Africa","singhj9@ukzn.ac.za"
"50","33069282","10.1016/S1473-3099(20)30832-X","A promising inactivated whole-virion SARS-CoV-2 vaccine.",NA,"2021","01","13","Lancet Infect Dis","The Lancet. Infectious diseases","Adolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Middle Aged; SARS-CoV-2; Vaccines, Inactivated; Virion; Young Adult","Isakova-Sivak","Irina","Institute of Experimental Medicine, Saint Petersburg 197376, Russia",NA
"52","33067570","10.1038/s41579-020-00462-y","Learning from the past: development of safe and effective COVID-19 vaccines.","The rapid spread of severe acute respiratory syndrome coronavirus..2 (SARS-CoV-2) has elicited an equally rapid response aiming to develop a COVID-19 vaccine. These efforts are encouraging; however, comprehensive efficacy and safety evaluations are essential in the development of a vaccine, and we can learn from previous vaccine development campaigns. In this Perspective, we summarize examples of vaccine-associated disease enhancement in the history of developing vaccines against respiratory syn","2021","03","01","Nat Rev Microbiol","Nature reviews. Microbiology","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Design; Drug Evaluation; Drug Industry; Humans; Respiratory Syncytial Virus Vaccines; Viral Vaccines","Su","Shan","Key Laboratory of Medical Molecular Virology (MOE/MOH/CAM), School of Basic Medical Sciences, Fudan University, Shanghai, China",NA
"53","33065034","10.1016/S0140-6736(20)32137-1","SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.","Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known abou","2020","11","25","Lancet","Lancet (London, England)","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Poland","Gregory A","Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA","poland.gregory@mayo.edu"
"54","33064982","10.1016/j.cell.2020.09.040","Why and How Vaccines Work.","Vaccines save millions of lives from infectious diseases caused by viruses and bacteria. As the world awaits safe and effective COVID-19 vaccines, we celebrate the progresses made and highlight challenges ahead in vaccines and the science behind them.","2020","10","26","Cell","Cell","Adjuvants, Immunologic; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Communicable Disease Control; Communicable Diseases; Coronavirus Infections; Drug Utilization; Humans; Immunity, Herd; Pandemics; Patient Acceptance of Health Care; Pneumonia, Viral; Vaccination; Vaccines; Viral Vaccines","Iwasaki","Akiko","Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA","akiko.iwasaki@yale.edu"
"55","33064383","10.1056/NEJMp2031373","Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations.",NA,"2020","12","08","N Engl J Med","The New England journal of medicine","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Approval; Follow-Up Studies; Humans; Pandemics; United States; United States Food and Drug Administration","Krause","Philip R","From the Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD",NA
"56","33064382","10.1056/NEJMp2030033","Trustworthiness before Trust - Covid-19 Vaccine Trials and the Black Community.",NA,"2020","12","11","N Engl J Med","The New England journal of medicine","African Americans; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Pandemics; Patient Participation; Trust","Warren","Rueben C","From the National Center for Bioethics in Research and Health Care, Tuskegee University, Tuskegee, AL (R.C.W., D.A.H.)",NA
"57","33062951","10.1021/acsptsci.0c00109","SARS-CoV-2 Vaccine Development: An Overview and Perspectives.","Coronavirus disease 2019, abbreviated as COVID-19, is caused by a new strain of coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It started in late December 2019 in Wuhan, China, and by mid-March 2020, the disease had spread globally. As of July 17, 2020, this pandemic virus has infected 13.9 million people and claimed the life of approximately 593...000 people globally, and the numbers continue to climb. An unprecedented effort is underway to develop therapeutic ","2020","10","20","ACS Pharmacol Transl Sci","ACS pharmacology &amp; translational science",NA,"Liu","Yi","Molecular Imaging Program at Stanford (MIPS), Stanford University, 3155 Porter Drive, Palo Alto, California 94304, United States",NA
"58","33059771","10.1186/s13063-020-04775-4","Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.","To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19. To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19","2020","11","03","Trials","Trials","Brazil; COVID-19; COVID-19 Vaccine; Inactivated Vaccines; Phase III Clinical Trial; Randomised controlled trial; protocol; Adolescent; Adult; Aged; Betacoronavirus; Brazil; COVID-19; Case-Control Studies; Coronavirus Infections; Data Management; Double-Blind Method; Female; Health Personnel; Humans; Incidence; Informed Consent; Injections, Intramuscular; Male; Middle Aged; Pandemics; Placebos; Pneumonia, Viral; SARS-CoV-2; Safety; Therapies, Investigational; Treatment Outcome; Vaccination; Vaccines; Young Adult","Palacios","Ricardo","Center for Clinical Trials and Pharmacovigilance, Instituto Butantan, S..o Paulo, Brazil. ricardo.palacios@butantan.gov","ricardo.palacios@butantan.gov.br"
"59","33057226","10.1038/d41586-020-02856-7","How anti-ageing drugs could boost COVID vaccines in older people.",NA,"2020","10","26","Nature","Nature","Ageing; Immunology; SARS-CoV-2; Vaccines; Adult; Aged; Aging; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Female; Humans; Male; Metformin; Mice; Pandemics; Pneumonia, Viral; Rejuvenation; Sirolimus; TOR Serine-Threonine Kinases; Viral Vaccines","Willyard","Cassandra",NA,NA
"60","33053301","10.1056/NEJMe2031646","Audio Interview: Vaccinology and Covid-19.",NA,"2020","10","27","N Engl J Med","The New England journal of medicine","Adult; Antigens, Surface; Antigens, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase I as Topic; Coronavirus Infections; Dose-Response Relationship, Immunologic; Genetic Vectors; Healthy Volunteers; History, 18th Century; Humans; Pandemics; Pneumonia, Viral; RNA, Messenger; RNA, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, Attenuated; Vaccinology; Viral Vaccines","Rubin","Eric J",NA,NA
"61","33053279","10.1056/NEJMoa2027906","Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide. Multiple vaccine candidates are under development, but no vaccine is currently available. Interim safety and immunogenicity data about the vaccine candidate BNT162b1 in younger adults have been reported previously from trials in Germany and the United States. In an ongoing, placebo-controlled, observer-blinded, dose-","2020","12","23","N Engl J Med","The New England journal of medicine","Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Neutralization Tests; SARS-CoV-2; Single-Blind Method; Spike Glycoprotein, Coronavirus; Young Adult","Walsh","Edward E","From the University of Rochester and Rochester General Hospital, Rochester (E.E.W., A.R.F.), Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.K., D.C., K.R.T., P.R.D., K.U.J., W.C.G.), and New York University Langone Vaccine Center and Grossman School of Medicine, New York (M.J.M., V.R.) - all in New York",NA
"62","33051445","10.1038/s41392-020-00352-y","A systematic review of SARS-CoV-2 vaccine candidates.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is highly pathogenic and has caused the recent worldwide pandemic officially named coronavirus disease (COVID-19). Currently, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials. In this review, we provide an overview of the expe","2020","11","05","Signal Transduct Target Ther","Signal transduction and targeted therapy","Angiotensin-Converting Enzyme 2; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Gene Expression Regulation; Humans; Immunity, Innate; Immunization Schedule; Immunogenicity, Vaccine; Middle East Respiratory Syndrome Coronavirus; Pandemics; Patient Safety; Peptidyl-Dipeptidase A; Pneumonia, Viral; Protein Binding; Receptors, Virus; SARS Virus; SARS-CoV-2; Severe Acute Respiratory Syndrome; Spike Glycoprotein, Coronavirus; Vaccines, Attenuated; Vaccines, DNA; Vaccines, Subunit; Vaccines, Virus-Like Particle; Viral Vaccines","Dong","Yetian","The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, China",NA
"63","33051241","10.1136/bmj.m3967","Covid-19: Johnson and Johnson vaccine trial is paused because of unexplained illness in participant.",NA,"2020","10","19","BMJ","BMJ (Clinical research ed.)",NA,"Mahase","Elisabeth","The BMJ",NA
"64","33048967","10.1371/journal.pone.0240648","State-level variation of initial COVID-19 dynamics in the United States.","During an epidemic, metrics such as R0, doubling time, and case fatality rates are important in understanding and predicting the course of an epidemic. However, if collected over country or regional scales, these metrics hide important smaller-scale, local dynamics. We examine how commonly used epidemiological metrics differ for each individual state within the United States during the initial COVID-19 outbreak. We found that the detected case number and trajectory of early detected cases differ","2020","11","02","PLoS One","PloS one","Aged; Aged, 80 and over; Betacoronavirus; COVID-19; Coronavirus Infections; Epidemiological Monitoring; Humans; Income; Infection Control; Influenza Vaccines; Linear Models; Pandemics; Pneumonia, Viral; Population Density; Rural Population; SARS-CoV-2; Time Factors; United States; Vaccination","White","Easton R","Department of Biology, University of Vermont, Burlington, VT, United States of America",NA
"65","33047328","10.1111/apa.15614","Nationwide COVID-19 survey of Italian parents reveals useful information on attitudes to school attendance, medical support, vaccines and drug trials.",NA,"2021","02","24","Acta Paediatr","Acta paediatrica (Oslo, Norway : 1992)","Adult; COVID-19; COVID-19 Vaccines; Child; Clinical Trials as Topic; Communicable Disease Control; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Italy; Male; Parents; Return to School; Surveys and Questionnaires","Pierantoni","Luca","Pediatric Emergency Unit, Department of Medical and Surgical Sciences, S. Orsola University Hospital, Bologna, Italy",NA
"66","33043110","10.1016/j.imu.2020.100438","Exploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19.","Stimulation and generation of T and B cell-mediated long-term immune response are essential for the curbing of a deadly virus such as SAR-CoV-2 (Severe Acute Respiratory Corona Virus 2). Immunoinformatics approach in vaccine design takes advantage of antigenic and non-allergenic epitopes present on the spike glycoprotein of SARS-CoV-2 to elicit immune responses. T cells and B cells epitopes were predicted, and the selected residues were subjected to allergenicity, antigenicity and toxicity scree","2020","12","17","Inform Med Unlocked","Informatics in medicine unlocked","COVID-19; Immunity; SARS-CoV-2; Subunit vaccine; TLRs","Oladipo","Elijah Kolawole","Department of Microbiology, Laboratory of Molecular Biology, Immunology and Bioinformatics, Adeleke University, Ede, Osun State, Nigeria",NA
"67","33042591","10.3126/nje.v10i3.31622","Impact of COVID-19 on clinical trials and clinical research: A systematic review.","Background: The World Health Organization has reported more than 31,186,000 confirmed cases of coronavirus disease-19 (COVID-19), including 962,343 deaths, worldwide as on September 21, 2020. The current COVID-19 pandemic is affecting clinical research activities in most parts of the world. The focus on developing a vaccine for SARS-CoV-2 and the treatment of COVID-19 is, in fact, disrupting many upcoming and/or ongoing clinical trials on other diseases around the globe. On March 18, 2020","2020","10","30","Nepal J Epidemiol","Nepal journal of epidemiology","COVID-19; SARS-CoV-2; clinical trial; pandemic; research capacity; systematic review","Sathian","Brijesh","Geriatrics and long term care Department, Rumailah Hospital, Hamad Medical Corporation, Doha, Qatar",NA
"68","33041111","10.1016/j.ajem.2020.08.091","SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.","There is a pressing need for COVID-19 transmission control and effective treatments. We aim to evaluate the safety and effectiveness of SARS-CoV-2 pharmacologic therapies as of August 2, 2020 according to study level of evidence. PubMed, ScienceDirect, Cochrane Library, JAMA Network and PNAS were searched. The following keywords were used: ((COVID-19) OR (SARS-CoV-2)) AND ((((((therapeutics) OR (treatment)) OR (vaccine)) OR (hydroxychloroquine)) OR (antiviral)) OR (prognosis)). Results included ","2020","12","17","Am J Emerg Med","The American journal of emergency medicine","COVID-19 clinical outcomes; COVID-19 pharmacologic treatments; Drug effectiveness; Drug safety; SARS-CoV-2; Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; Chloroquine; Dexamethasone; Drug Combinations; Evidence-Based Medicine; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; Systematic Reviews as Topic","Baroutjian","Amanda","Department of Surgery, Division of Trauma and Acute Care Surgery, Kendall Regional Medical Center, Miami, FL, USA",NA
"69","33038433","10.1016/j.jhep.2020.09.031","COVID-19: Discovery, diagnostics and drug development.","Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019, and has since become a pandemic. Groups from China identified and sequenced the virus responsible for COVID-19, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and determined that it was a novel coronavirus sharing high sequence identity with bat- and pangolin-derived SARS-like coronaviruses, suggesting a zoonotic origin. SARS-CoV-2 is a member of the Coronaviridae family of enveloped, positive-sense","2020","12","29","J Hepatol","Journal of hepatology","Coronavirus; Drug repurposing; Pathogenesis; Remdesivir; SARS-CoV-2; Antiviral Agents; COVID-19; Drug Development; Drug Discovery; Drug Repositioning; Genome, Viral; Humans; Immunity, Innate; Pandemics; Respiratory Distress Syndrome; Risk Factors; SARS-CoV-2","Asselah","Tarik","Universit.. de Paris, CRI, INSERM UMR 1149, Department of Hepatology, AP-HP H..pital Beaujon, Clichy, France. Electronic address: Tarik.asselah@aphp","Tarik.asselah@aphp.fr"
"70","33035262","10.1371/journal.ppat.1008902","Preparedness needs research: How fundamental science and international collaboration accelerated the response to COVID-19.","The first cluster of patients suffering from coronavirus disease 2019 (COVID-19) was identified on December 21, 2019, and as of July 29, 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been linked with 664,333 deaths and number at least 16,932,996 worldwide. Unprecedented in global societal impact, the COVID-19 pandemic has tested local, national, and international preparedness for viral outbreaks to the limits. Just as it will be vital to identify missed oppor","2020","10","21","PLoS Pathog","PLoS pathogens","Betacoronavirus; Biomedical Research; COVID-19; Contact Tracing; Coronavirus Infections; Humans; International Cooperation; Pandemics; Pneumonia, Viral; SARS-CoV-2","Kinsella","Cormac M","Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands",NA
"71","33034449","10.1021/acsnano.0c07197","COVID-19 Vaccine Frontrunners and Their Nanotechnology Design.","Humanity is experiencing a catastrophic pandemic. SARS-CoV-2 has spread globally to cause significant morbidity and mortality, and there still remain unknowns about the biology and pathology of the virus. Even with testing, tracing, and social distancing, many countries are struggling to contain SARS-CoV-2. COVID-19 will only be suppressible when herd immunity develops, either because of an effective vaccine or if the population has been infected and is resistant to reinfection. There is virtual","2020","11","12","ACS Nano","ACS nano","astrazeneca; biontech; cansino; moderna; mrna; pfizer; sars-cov-2; university of oxford; vaccine; viral vector; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Industry; Humans; Nanotechnology; Vaccines, Subunit; Vaccines, Synthetic; Viral Vaccines","Chung","Young Hun","Department of Bioengineering, University of California San Diego, La Jolla, California 92093, United States",NA
"72","33034338","10.1093/bib/bbaa259","Computer-aided prediction and design of IL-6 inducing peptides: IL-6 plays a crucial role in COVID-19.","Interleukin 6 (IL-6) is a pro-inflammatory cytokine that stimulates acute phase responses, hematopoiesis and specific immune reactions. Recently, it was found that the IL-6 plays a vital role in the progression of COVID-19, which is responsible for the high mortality rate. In order to facilitate the scientific community to fight against COVID-19, we have developed a method for predicting IL-6 inducing peptides/epitopes. The models were trained and tested on experimentally validated 365 IL-6 indu","2020","11","17","Brief Bioinform","Briefings in bioinformatics","COVID-19; Interleukin 6 (IL-6); computer-aided prediction; machine learning; pro-inflammatory cytokine","Dhall","Anjali","Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India",NA
"73","33034095","10.1111/joim.13185","Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.","Convalescent plasma therapy for COVID-19 relies on transfer of anti-viral antibody from donors to recipients via plasma transfusion. The relationship between clinical characteristics and antibody response to COVID-19 is not well defined. We investigated predictors of convalescent antibody production and quantified recipient antibody response in a convalescent plasma therapy clinical trial. Multivariable analysis of clinical and serological parameters in 103 confirmed COVID-19 convalescent plasma","2021","02","25","J Intern Med","Journal of internal medicine","COVID-19; antibody titre; convalescent plasma","Madariaga","M L L","From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA",NA
"74","33033884","10.1007/s13577-020-00444-5","Umbilical cord: an allogenic tissue for potential treatment of COVID-19.","The COVID-19 pandemic has placed an unprecedented burden on health care systems and economies around the globe. Clinical evidences demonstrate that SARS-CoV-2 infection produces detrimental levels of pro-inflammatory cytokines and chemokines that can lead to acute respiratory distress syndrome (ARDS) and significant systemic organ damage. Currently, there is no definitive therapy for COVID-19 or associated complications, and with the hope of a safe and effective vaccine in the distant future, th","2021","01","15","Hum Cell","Human cell","COVID-19; Coronavirus; Mesenchymal stem cells; Umbilical cord; Wharton...s jelly; COVID-19; Clinical Trials as Topic; Humans; Immunomodulation; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pandemics; Respiratory Distress Syndrome; Umbilical Cord; Wharton Jelly","Rodriguez","Hugo C","Future Biologics, 1110 Ballpark Ln Apt 5109, Lawrenceville, GA, 30043, USA",NA
"75","33033397","10.1038/d41586-020-02807-2","What China's speedy COVID vaccine deployment means for the pandemic.",NA,"2020","10","26","Nature","Nature","Infection; SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Coronavirus Infections; Developing Countries; Humans; International Cooperation; Pandemics; Pneumonia, Viral; Politics; Time Factors; Viral Vaccines","Cyranoski","David",NA,NA
"76","33033196","10.1126/science.370.6513.154","A call to test new vaccines head to head, in monkeys.",NA,"2020","11","11","Science","Science (New York, N.Y.)","Animal Experimentation; Animals; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Haplorhini; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Cohen","Jon",NA,NA
"77","33032740","10.1016/j.jacc.2020.08.028","Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review.","Viral respiratory infections are risk factors for cardiovascular disease (CVD). Underlying CVD is also associated with an increased risk of complications following viral respiratory infections, including increased morbidity, mortality, and health care utilization. Globally, these phenomena are observed with seasonal influenza and with the current coronavirus disease 2019 (COVID-19) pandemic. Persons with CVD represent an important target population for respiratory virus vaccines, with capacity d","2020","10","19","J Am Coll Cardiol","Journal of the American College of Cardiology","acute myocardial infarction; cardioprotection; heart failure; influenza vaccination; Betacoronavirus; COVID-19; Cardiotonic Agents; Cardiovascular Diseases; Clinical Trials as Topic; Coronavirus Infections; Humans; Influenza Vaccines; Influenza, Human; Pandemics; Pneumonia, Viral; Public Health; Risk Factors; SARS-CoV-2; Vaccination","Behrouzi","Bahar","Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada",NA
"78","33031856","10.1016/j.pharmthera.2020.107703","Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?","Coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has currently led to a global pandemic with millions of confirmed and increasing cases around the world. The novel SARS-CoV-2 not only affects the lungs causing severe acute respiratory dysfunction but also leads to significant dysfunction in multiple organs and physiological systems including the cardiovascular system. A plethora of studies have shown the viral infection triggers an ","2021","02","23","Pharmacol Ther","Pharmacology &amp; therapeutics","Bioactive metabolites; COVID-19; Cardiovascular disorders; Inflammation; n-3 polyunsaturated fatty acids; Animals; COVID-19; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cytokine Release Syndrome; Fatty Acids, Omega-3; Humans; Oxidative Stress; Randomized Controlled Trials as Topic","Darwesh","Ahmed M","Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada",NA
"79","33030819","10.7705/biomedica.5826",NA,NA,"2020","10","22","Biomedica","Biomedica : revista del Instituto Nacional de Salud","Adenoviridae; Antibodies, Neutralizing; Antibodies, Viral; Antigens, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Approval; Epitopes; Humans; Immunogenicity, Vaccine; Latin America; Pandemics; Pneumonia, Viral; RNA, Messenger; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Cell Antigen Receptor Specificity; United States; Vaccines, Attenuated; Vaccines, Inactivated; Vaccines, Synthetic; Viral Vaccines","Torres","Alfredo G","Department of Microbiology and Immunology, Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA. altorres@utmb","altorres@utmb.edu"
"80","33030329","","[SARS coronavirus-2 vaccines: options and state-of-the-art].","Since the first reports in mid-January of a serious new viral respiratory infection, COVID-19, and the identification of SARS-CoV-2 as the cause of this disease, researchers work intensely on developing a vaccine that can protect individuals against serious disease and that can limit the spread of the virus. Vaccine developers are using a range of platform technologies to do this, each with advantages and disadvantages. Close to 30 vaccines are now in clinical testing. The first results are enco","2020","10","21","Ned Tijdschr Geneeskd","Nederlands tijdschrift voor geneeskunde","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Global Health; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Huckriede","Anke L W","Universitair Medisch Centrum Groningen/Universiteit Groningen, afd. Medische Microbiologie en Infectiepreventie, Groningen","a.l.w.huckriede@umcg.nl"
"81","33029657","10.1007/s00125-020-05284-4","Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study.","The aim of the study was to characterise the humoral response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with diabetes. Demonstrating the ability to mount an appropriate antibody response in the presence of hyperglycaemia is relevant for the comprehension of mechanisms related to the observed worse clinical outcome of coronavirus disease 2019 (COVID-19) pneumonia in patients with diabetes and for the development of any future vaccination campaign to prevent ","2020","11","12","Diabetologia","Diabetologia","Antibodies; COVID-19; Diabetes; Human; Humoral response; Receptor-binding domain; SARS-CoV-2; Survival rate; Adult; Aged; Aged, 80 and over; Antibodies, Viral; Antibody Formation; Antigens, Viral; Biomarkers; Blood Coagulation Disorders; Blood Glucose; COVID-19; Cohort Studies; Coronavirus Infections; Diabetes Mellitus; Female; Humans; Immunity, Humoral; Immunoglobulin G; Male; Middle Aged; Pandemics; Pneumonia, Viral; Risk Factors; Survival Analysis","Lampasona","Vito","San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy",NA
"82","33029020","10.1038/s41591-020-1111-1","Scientists, keep an open line of communication with the public.",NA,"2020","12","07","Nat Med","Nature medicine","Access to Information; Biomedical Research; COVID-19; Clinical Trials as Topic; Communication; Female; History, 21st Century; Humans; Laboratory Personnel; Male; Pandemics; Patient Education as Topic; Patient Participation; Social Media; Viral Vaccines",NA,NA,NA,NA
"83","33024978","10.1101/2020.08.07.20169920","Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events.","SARS-CoV-2 is difficult to contain because many transmissions occur during the pre-symptomatic phase of infection. Moreover, in contrast to influenza, while most SARS-CoV-2 infected people do not transmit the virus to anybody, a small percentage secondarily infect large numbers of people. We designed mathematical models of SARS-CoV-2 and influenza which link observed viral shedding patterns with key epidemiologic features of each virus, including distributions of the number of secondary cases at","2021","03","03","medRxiv","medRxiv : the preprint server for health sciences",NA,"Goyal","Ashish","Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center",NA
"84","33024977","10.1101/2020.09.22.20199125","Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.","We sequenced the genomes of 5,085 SARS-CoV-2 strains causing two COVID-19 disease waves in metropolitan Houston, Texas, an ethnically diverse region with seven million residents. The genomes were from viruses recovered in the earliest recognized phase of the pandemic in Houston, and an ongoing massive second wave of infections. The virus was originally introduced into Houston many times independently. Virtually all strains in the second wave have a Gly614 amino acid replacement in the spike prot","2021","01","10","medRxiv","medRxiv : the preprint server for health sciences",NA,"Long","S Wesley","Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, 6565 Fannin Street, Houston, Texas 77030",NA
"85","33022727","10.1055/a-0982-8894","[Vaccines for adults: an update].","Vaccination practices in Germany are driven by scientific developments and a complex regulatory environment. Some important developments in 2019/20 are described here: Work-related vaccination recommendations for measles, rubella, and chickenpox have been streamlined and expanded. In addition, measles vaccination or documentation of immunity is now mandatory for employment at and attendance of many institutions, specifically including day care centers and schools. Owing to the shift of pneumococ","2020","10","14","Dtsch Med Wochenschr","Deutsche medizinische Wochenschrift (1946)","Adult; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Germany; Humans; Immunization Schedule; Mass Vaccination; Vaccines; Viral Vaccines","Seybold","Ulrich","Medizinische Klinik und Poliklinik IV, Sektion Klinische Infektiologie, Klinikum der Ludwig-Maximilians-Universit..t, M..nchen",NA
"86","33022293","10.1016/j.medmal.2020.09.013","Clinical trial protocols of repurposed prophylaxis for COVID-19: A review.","Efficient therapeutic strategies are needed to counter the COVID-19 pandemic, caused by the SARS-CoV-2 virus. In a context where specific vaccines are not yet available, the containment of the pandemic would be facilitated with efficient prophylaxis. We screened several clinical trials repositories and platforms in search of the prophylactic strategies being investigated against COVID-19 in July 2020. Up to July 5, 2020, only one clinical trial result was published, although we found 112 clinica","2020","12","07","Med Mal Infect","Medecine et maladies infectieuses","COVID-19; Prophylaxis; Repurposed chemotherapy; SARS-CoV-2","Sallard","E","..cole normale sup..rieure de Paris, 45, rue D'Ulm, 75005 Paris, France","erwan.sallard@ens.psl.eu"
"87","33015676","10.31128/AJGP-08-20-5559","Preparing the public for COVID-19 vaccines: How can general practitioners build vaccine confidence and optimise uptake for themselves and their patients?","The availability of a COVID-19 vaccine is being heralded as the solution to control the current COVID-19 pandemic, reduce the number of infections and deaths and facilitate resumption of our previous way of..life. The aim of this article is to provide a framework for primary care of what will be needed to optimise COVID-19 vaccine confidence and uptake in Australia once the vaccine prioritisation schedule and key target groups are known. While a number of vaccines are currently under development","2020","10","13","Aust J Gen Pract","Australian journal of general practice","Australia; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Focus Groups; General Practitioners; Health Services Accessibility; Humans; Immunization Programs; Pandemics; Patient Acceptance of Health Care; Pneumonia, Viral; Primary Health Care; Public Health; SARS-CoV-2; Self Concept; Vaccination; Viral Vaccines","Danchin","Margie","MBBS, PhD, FRACP, Associate Professor and David Bickart Clinician Scientist Fellow, Department of Paediatrics, The University of Melbourne, Vic",NA
"88","33015109","10.3389/fmed.2020.556366","What Can We Estimate From Fatality and Infectious Case Data Using the Susceptible-Infected-Removed (SIR) Model? A Case Study of Covid-19 Pandemic.","The rapidly spreading Covid-19 that affected almost all countries, was first reported at the end of 2019. As a consequence of its highly infectious nature, countries all over the world have imposed extremely strict measures to control its spread. Since the earliest stages of this major pandemic, academics have done a huge amount of research in order to understand the disease, develop medication, vaccines and tests, and model its spread. Among these studies, a great deal of effort has been invest","2020","10","06","Front Med (Lausanne)","Frontiers in medicine","COVID-19; SIR model; epidemiology; mathematical models; parameter estimation","Ahmetolan","Semra","Department of Mathematics, Faculty of Science and Letters, Istanbul Technical University, Istanbul, Turkey",NA
"89","33013255","10.1007/s10989-020-10115-6","Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease.","At the end of December 2019, a new strain of coronavirus was identified in the Wuhan city of Hubei province in China. Within a shorter period of time, an unprecedented outbreak of this strain was witnessed over the entire Wuhan city. This novel coronavirus strain was later officially renamed as COVID-19 (Coronavirus disease 2019) by the World Health Organization. The mode of transmission was human-to-human contact and hence resulted in a rapid surge across the globe where more than 24..million p","2020","10","06","Int J Pept Res Ther","International journal of peptide research and therapeutics","COVID-19; Coronavirus; FDA approved drugs; High..throughput..virtual screening; Pentagastrin; Sincalide","Balakrishnan","Vijayakumar","S..o Carlos Institute of Physics (IFSC), University of S..o Paulo, Av. Joao Dagnone, 1100 - Jardim Santa Angelina, S..o Carlos, 13563-120 Brazil",NA
"90","33012858","10.2471/BLT.20.030920","Melanie Saville: the end-to-end process needed for a SARS-CoV-2 vaccine.","Melanie Saville talks to Gary Humphreys about the specific challenges faced in developing and distributing SARS-CoV-2 vaccines and the need to fund end-to-end approaches to support those aims.","2020","10","15","Bull World Health Organ","Bulletin of the World Health Organization","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines",NA,NA,NA,NA
"91","33012602","10.1016/j.vaccine.2020.09.031","Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.","To rapidly evaluate the safety and efficacy of COVID-19 vaccine candidates, prioritizing vaccine trial sites in areas with high expected disease incidence can speed endpoint accrual and shorten trial duration. Mathematical and statistical forecast models can inform the process of site selection, integrating available data sources and facilitating comparisons across locations. We recommend the use of ensemble forecast modeling - combining projections from independent modeling groups - to guide in","2020","11","02","Vaccine","Vaccine","Efficacy trial; Ensemble modeling; Forecast model; Trial planning; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Forecasting; Humans; Models, Theoretical; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Dean","Natalie E","Department of Biostatistics, University of Florida, Gainesville, FL, United States. Electronic address: nataliedean@ufl","nataliedean@ufl.edu"
"92","33012348","10.1016/j.mayocp.2020.07.021","SARS-CoV-2 Vaccine Development: Current Status.","In the midst of the severe acute respiratory syndrome coronavirus 2 pandemic and its attendant morbidity and mortality, safe and efficacious vaccines are needed that induce protective and long-lived immune responses. More than 120 vaccine candidates worldwide are in various preclinical and phase 1 to 3 clinical trials that include inactivated, live-attenuated, viral-vectored replicating and nonreplicating, protein- and peptide-based, and nucleic acid approaches. Vaccines will be necessary both f","2020","10","19","Mayo Clin Proc","Mayo Clinic proceedings","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Laboratory Techniques; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Public Health; SARS-CoV-2; United States; Viral Vaccines","Poland","Gregory A","Vaccine Research Group, Mayo Clinic, Rochester, MN. Electronic address: poland.gregory@mayo","poland.gregory@mayo.edu"
"93","33009982","10.1007/s12015-020-10046-1","Cell-Based Therapy for Severe COVID-19 Patients: Clinical Trials and Cost-Utility.","The race among countries and companies to develop efficacious vaccines and therapeutics for the COVID-19 is ongoing fast, with many trials underway. Among this, cell-based therapy is focused on moderate to severe phases of COVID-19, and there have been promising outcomes. Mesenchymal stem cells (MSCs) due to their pro/anti-inflammatory and immune-modulatory behavior, Natural Killer (NK) cells thanks to their capacity of lysing virus-infected cells and regulate the resulting immune response, Dend","2021","03","02","Stem Cell Rev Rep","Stem cell reviews and reports","COVID-19; Cell-based therapy; Clinical trials; Cost; Stem cell; COVID-19; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Pandemics; SARS-CoV-2","Golchin","Ali","Department of Clinical Biochemistry and Applied Cell Sciences, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran. agolchin.vet10@yahoo","agolchin.vet10@yahoo.com"
"94","33009361","10.12659/AJCR.927812","A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.","BACKGROUND This is a case report of an immunocompromised patient with a history of non-Hodgkin lymphoma and persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who was seronegative and successfully treated with convalescent plasma. CASE REPORT A 63-year-old woman with a past medical history of non-Hodgkin lymphoma in remission while on maintenance therapy with the anti-CD20 monoclonal antibody, obinutuzumab, tested positive for SARS-CoV-2 via nasopharyngeal reverse ","2020","10","13","Am J Case Rep","The American journal of case reports","Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Coronavirus Infections; Female; Follow-Up Studies; Humans; Immunization, Passive; Immunocompromised Host; Lymphoma, Non-Hodgkin; Middle Aged; Pandemics; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; Serologic Tests; Severity of Illness Index; Treatment Outcome","Moore","Joanna L","Department of Medicine, Norwalk Hospital, Norwalk, CT, USA",NA
"95","33009266","10.1097/DCC.0000000000000447","Tracking a Vaccine and Developing Therapeutics for COVID-19.",NA,"2020","10","15","Dimens Crit Care Nurs","Dimensions of critical care nursing : DCCN","Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Gould","Kathleen Ahern","Editor-in-Chief Dimensions of Critical Care Nursing",NA
"96","33002475","10.1016/j.cca.2020.09.033","SARS-CoV-2 infection serology validation of different methods: Usefulness of IgA in the early phase of infection.","A novel coronavirus (SARS-CoV-2) was isolated from the respiratory samples of patients with pneumonia as showed by the sequence analysis of the virus genomes obtained in Wuhan, China. The antibody response to SARS-CoV-2 is not well understood yet, but the availability of sensitive and specific serological assays will be crucial for the early diagnosis of infection, for epidemiological studies and for defining the presence of neutralizing antibodies in response to a possible vaccine. We tested an","2020","12","09","Clin Chim Acta","Clinica chimica acta; international journal of clinical chemistry","CLIA assay; Covid-19 serological test; ECLIA assay; ELISA assay; SARS-CoV-2; COVID-19; COVID-19 Serological Testing; Clinical Laboratory Techniques; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin A; Real-Time Polymerase Chain Reaction; Reproducibility of Results; SARS-CoV-2","Pieri","Massimo","Department of Experimental Medicine, University of Tor Vergata, Rome, Italy","massimo.pieri@uniroma2.it"
"97","33001626","10.1021/acsnano.0c06109","Engineering Antiviral Vaccines.","Despite the vital role of vaccines in fighting viral pathogens, effective vaccines are still unavailable for many infectious diseases. The importance of vaccines cannot be overstated during the outbreak of a pandemic, such as the coronavirus disease 2019 (COVID-19) pandemic. The understanding of genomics, structural biology, and innate/adaptive immunity have expanded the toolkits available for current vaccine development. However, sudden outbreaks and the requirement of population-level immuniza","2020","11","12","ACS Nano","ACS nano","COVID-19; biomedical devices; drug delivery; drug discovery; immunotherapy; infectious disease; pandemics; vaccine; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunogenicity, Vaccine; Vaccine Potency; Vaccines, Subunit; Vaccines, Synthetic; Viral Vaccines","Zhou","Xingwu","Department of Bioengineering, University of California, Los Angeles, Los Angeles, California 90095, United States",NA
"98","33000193","10.3892/ijmm.2020.4733","[Comment] COVID...19 vaccine safety.","In response to the SARS...CoV...2 outbreak, and the resulting COVID...19 pandemic, a global competition to develop an anti...COVID...19 vaccine has ensued. The targeted time frame for initial vaccine deployment is late 2020. The present article examines whether short...term, mid...term, and long...term vaccine safety can be achieved under such an accelerated schedule, given the myriad vaccine...induced mechanisms that have demonstrated adverse effects based on previous clinical trials and labora","2020","10","03","Int J Mol Med","International journal of molecular medicine",NA,"Kostoff","Ronald N","School of Public Policy, Georgia Institute of Technology, Gainesville, VA 20155, USA",NA
"99","32998488","10.4045/tidsskr.20.0676","Status of COVID-19 vaccine development.","The pandemic caused by SARS-CoV-2 has created a global humanitarian and economic crisis for which there is currently no solution in sight. Much hope has therefore been pinned on a vaccine that can protect against the disease COVID-19. As of August 2020, the World Health Organization has registered 173 vaccine candidates as being in development. Six candidates have entered phase 3 trials, and the first results from these are expected in the autumn.","2020","10","07","Tidsskr Nor Laegeforen","Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke","Antigens, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Viral Vaccines","Taxt","Arne Michael",NA,NA
"100","32998157","10.1038/s41586-020-2814-7","COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responses.","An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein<sup>1</sup>. Here we present antibody","2020","10","29","Nature","Nature","Adult; Antibodies, Neutralizing; Antibodies, Viral; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Cytokines; Female; Germany; Humans; Immunoglobulin G; Male; Middle Aged; Pandemics; Pneumonia, Viral; Th1 Cells; Viral Vaccines; Young Adult","Sahin","Ugur","BioNTech, Mainz, Germany. ugur.sahin@biontech","ugur.sahin@biontech.de"
"101","32997699","10.1371/journal.pone.0239694","Analysis of COVID-19 clinical trials: A data-driven, ontology-based, and natural language processing approach.","With the novel COVID-19 pandemic disrupting and threatening the lives of millions, researchers and clinicians have been recently conducting clinical trials at an unprecedented rate to learn more about the virus and potential drugs/treatments/vaccines to treat its infection. As a result of the influx of clinical trials, researchers, clinicians, and the lay public, now more than ever, face a significant challenge in keeping up-to-date with the rapid rate of discoveries and advances. To remedy this","2020","10","07","PLoS One","PloS one","Betacoronavirus; Biological Ontologies; COVID-19; Clinical Trials as Topic; Computational Biology; Coronavirus Infections; Humans; Internet; Medical Subject Headings; Natural Language Processing; Pandemics; Phenotype; Pneumonia, Viral; SARS-CoV-2; Software","Alag","Shray","The Harker School, San Jose, CA, United States of America",NA
"102","32997318","10.1007/s40264-020-01002-6","Assessing the Safety of COVID-19 Vaccines: A Primer.","Vaccines against COVID-19 are being developed at speeds not previously achieved. With this unprecedented effort comes challenges for post-marketing safety monitoring and challenges for vaccine safety communication. To deploy these new vaccines fast across diverse populations, it is vital that robust pharmacovigilance and active surveillance systems are in place. Not all countries have the capability or resources to undertake adequate surveillance and will rely on data from those who can. The too","2020","12","11","Drug Saf","Drug safety","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase IV as Topic; Drug Approval; Drug Development; Humans; Pharmacoepidemiology; Pharmacovigilance; Product Surveillance, Postmarketing; SARS-CoV-2","Petousis-Harris","Helen","Department of General Practice and Primary Health Care, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. h.petousis-harris@auckland.ac","harris@auckland.ac.nz"
"103","32995807","10.1101/2020.09.16.20195552","How the clinical research community responded to the COVID-19 pandemic: An analysis of the COVID-19 clinical studies in ClinicalTrials.gov.","The novel coronavirus disease (COVID-19), broke out in December 2019, is a global pandemic. Rapidly in the past few months, a large number of clinical studies have been initiated worldwide to find effective therapeutics, vaccines, and preventive strategies. In this study, we aim to understand the landscape of COVID-19 clinical research and identify the gaps and issues that may cause difficulty in recruitment and the lack of population representativeness. We analyzed 2,034 COVID-19 studies regist","2020","12","29","medRxiv","medRxiv : the preprint server for health sciences",NA,"He","Zhe",NA,NA
"104","32994572","10.1038/d41586-020-02738-y","COVID vaccine confidence requires radical transparency.",NA,"2020","10","05","Nature","Nature","Infection; Medical research; Public health; SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; China; Clinical Trial Protocols as Topic; Clinical Trials as Topic; Confidentiality; Coronavirus Infections; Disclosure; Drug Industry; Humans; Pandemics; Pneumonia, Viral; Politics; Public Opinion; Russia; Safety; Trust; United States; Viral Vaccines",NA,NA,NA,NA
"105","32991900","10.1016/j.ijbiomac.2020.09.204","Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.","The emergence of the global pandemic caused by the novel SARS-CoV-2 virus has motivated scientists to find a definitive treatment or a vaccine against it in the shortest possible time. Current efforts towards this goal remain fruitless without a full understanding of the behavior of the virus and its adaptor proteins. This review provides an overview of the biological properties, functional mechanisms, and molecular components of SARS-CoV-2, along with investigational therapeutic and preventive ","2020","12","17","Int J Biol Macromol","International journal of biological macromolecules","COVID-19; Global pandemic; Investigational drugs; SARS-CoV-2; Vaccine development; Virus mechanism; Antiviral Agents; COVID-19; Clinical Trials as Topic; Humans; SARS-CoV-2; Viral Vaccines","Oroojalian","Fatemeh","Department of Advanced Sciences and Technologies in Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran",NA
"106","32991794","10.1056/NEJMoa2028436","Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.","Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age. We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) in healthy adults. The trial was expanded to incl","2020","12","23","N Engl J Med","The New England journal of medicine","Aged; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neutralization Tests; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes","Anderson","Evan J","From the Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine (E.J.A., V.V.E., K.F., M.S.S., C.A.R.), and Emory Vaccine Center, Yerkes National Primate Research Center, Emory University (M.S.S.), Atlanta, and Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur (E.J.A., N.G.R., V.K.P.) - both in Georgia",NA
"107","32991604","10.1371/journal.pone.0239554","Effectiveness of the non-pharmaceutical public health interventions against COVID-19; a protocol of a systematic review and realist review.","Without any pharmaceutical intervention and vaccination, the only way to combat Coronavirus Disease 2019 (COVID-19) is to slow down the spread of the disease by adopting non-pharmaceutical public health interventions (PHIs). Patient isolation, lockdown, quarantine, social distancing, changes in health care provision, and mass screening are the most common non-pharmaceutical PHIs to cope with the epidemic. However, there is neither systematic evidence on the effectiveness of non-pharmaceutical PH","2020","10","05","PLoS One","PloS one","Basic Reproduction Number; Betacoronavirus; COVID-19; Communicable Disease Control; Controlled Before-After Studies; Coronavirus Infections; Hospitalization; Humans; Interrupted Time Series Analysis; Meta-Analysis as Topic; Non-Randomized Controlled Trials as Topic; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Research Design; SARS-CoV-2; Systematic Reviews as Topic","Iezadi","Shabnam","Hospital Management Research Center, Iran University of Medical Sciences, Tehran, Iran",NA
"108","32991223","10.1080/21645515.2020.1815489","Considerations on the clinical development of COVID-19 vaccine from trial design perspectives.","COVID-19 has become a global pandemic, and an effective vaccine is needed. During the outbreak, the urgency for developing candidate vaccines has brought distinct challenges to clinical development. An efficacy trial, which measures whether the vaccine reduces the incidence of disease, is ordinarily required to fully evaluate vaccine efficacy. However, emergency use may be possible if promising immunogenicity results are observed. A ring vaccination trial, which recruits subjects connected to a ","2020","09","29","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","COVID-19 vaccine; data safety monitoring board; ring vaccination trial; seamless design; vaccine efficacy","Jiang","Zhiwei","Department of Biostatistics, Beijing KeyTech Statistical Consulting Co., Ltd , Beijing, China",NA
"109","32989315","10.1038/s41587-020-0697-7","Whither COVID-19 vaccines?",NA,"2020","10","15","Nat Biotechnol","Nature biotechnology","Animals; Betacoronavirus; Biotechnology; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Disease Models, Animal; Drug Development; Genetic Vectors; Global Health; Host Microbial Interactions; Humans; Immunity, Cellular; Immunity, Herd; Immunity, Humoral; Pandemics; Pneumonia, Viral; SARS-CoV-2; Safety; Spike Glycoprotein, Coronavirus; Translational Medical Research; Vaccines, DNA; Vaccines, Synthetic; Viral Vaccines","DeFrancesco","Laura","Nature Biotechnology, . l.defrancesco@us.nature","l.defrancesco@us.nature.com"
"110","32989290","10.1038/s41577-020-00455-1","Keeping track of the SARS-CoV-2 vaccine pipeline.",NA,"2020","11","03","Nat Rev Immunol","Nature reviews. Immunology","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Databases, Factual; Drug Approval; Humans; Immunogenicity, Vaccine; International Cooperation; Pandemics; Patient Safety; Pneumonia, Viral; SARS-CoV-2; Vaccination; Viral Vaccines","Parker","Edward P K","The Vaccine Centre, London School of Hygiene &amp","edward.parker@lshtm.ac.uk"
"111","32988688","10.1016/j.vaccine.2020.09.041","Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic.","The world is facing the COVID-19 pandemic. The development of a vaccine is challenging. We aimed to determine the proportion of people who intend to get vaccinated against COVID-19 in France or to participate in a vaccine clinical trial. We conducted an anonymous on-line survey from the 26th of March to the 20th of April 2020. Primary endpoints were the intention to get vaccinated against COVID-19 if a vaccine was available or participate in a vaccine clinical trial. Three thousand two hundred a","2020","10","22","Vaccine","Vaccine","COVID-19; Pandemics; SARS-CoV-2; Vaccine; Vaccine hesitancy; Adult; Age Factors; Aged; Aged, 80 and over; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Female; France; Health Personnel; Humans; Intention; Male; Middle Aged; Pandemics; Patient Acceptance of Health Care; Patient Safety; Pneumonia, Viral; SARS-CoV-2; Sex Factors; Surveys and Questionnaires; Vaccination; Viral Vaccines","Detoc","Ma..lle","Centre d'investigation clinique-INSERM 1408, University Hospital of Saint-Etienne, France",NA
"112","32985963","10.1089/vim.2020.0119","Coronavirus Disease 2019 Vaccine Development: An Overview.","To this day, the coronavirus disease 2019 (COVID-19) pandemic has not shown signs of abating. Moreover, the virus responsible for the pandemic, severe acute respiratory syndrome coronavirus 2, has evolved into three different variants. This phenomenon highlights an even greater need to develop drugs and vaccines to control the rate of infection and spread of the disease. As of July 7, 2020, at least 160 vaccine candidates, 21 of which have entered the clinical trial phase, have been developed. T","2020","09","28","Viral Immunol","Viral immunology","SARS-CoV-2; challenges; platforms; progress","Sumirtanurdin","Riyadi","Pharmacist Profession Education, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia",NA
"113","32983183","10.3389/fimmu.2020.02173","What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.",NA,"2020","10","14","Front Immunol","Frontiers in immunology","COVID-19; QS21 saponins; SARS-CoV2; inactivated virus vaccines; universal vaccine; Adolescent; Adult; Animals; Antibodies, Neutralizing; Antibodies, Viral; Antibody-Dependent Enhancement; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Female; Healthy Volunteers; Humans; Immunogenicity, Vaccine; Male; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccination; Vaccines, Inactivated; Viral Vaccines; Young Adult","Palatnik-de-Sousa","Clarisa B","Institute of Microbiology Paulo de G..es, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil",NA
"114","32979327","10.1016/S1473-3099(20)30709-X","The arrival of Sputnik V.",NA,"2020","10","13","Lancet Infect Dis","The Lancet. Infectious diseases","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Quality Control; Russia; SARS-CoV-2; Viral Vaccines","Balakrishnan","Vijay Shankar",NA,NA
"115","32978962","10.1111/biom.13377","Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes.","Time is of the essence in evaluating potential drugs and biologics for the treatment and prevention of COVID-19. There are currently 876 randomized clinical trials (phase 2 and 3) of treatments for COVID-19 registered on clinicaltrials.gov. Covariate adjustment is a statistical analysis method with potential to improve precision and reduce the required sample size for a substantial number of these trials. Though covariate adjustment is recommended by the U.S. Food and Drug Administration and the","2020","12","07","Biometrics","Biometrics","COVID-19; covariate adjustment; ordinal outcomes; randomized trial; survival analysis","Benkeser","David","Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA",NA
"116","32978611","10.1038/d41586-020-02706-6","COVID-vaccine results are on the way - and scientists' concerns are growing.",NA,"2020","10","05","Nature","Nature","Infection; Public health; SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; Clinical Trial Protocols as Topic; Clinical Trials as Topic; Coronavirus Infections; Disclosure; Drug Approval; Drug Industry; Humans; Myelitis, Transverse; Pandemics; Pneumonia, Viral; Politics; Public Opinion; Research Personnel; Safety; Sample Size; United Kingdom; United States; United States Food and Drug Administration; Viral Vaccines","Mallapaty","Smriti",NA,NA
"117","32974268","10.3389/fpubh.2020.00497","Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs.","SARS-CoV-2 rapidly spread from China until it was defined a pandemic by WHO in March 2020. Related scientific papers have rapidly extended information regarding the diagnosis, treatment and epidemiology of COVID-19 infection. To date, no vaccine or definitive treatment is available to defeat the virus and therapies are mainly based on existing drugs used to treat other conditions. Existing therapies used in several clinical trials work by affecting the biology of COVID-19 and/or counteracting th","2020","09","28","Front Public Health","Frontiers in public health","COVID-19; COVID-19 (condition); COVID-19 infection; clinical trial (2.172); coronavirus (2019-nCoV)","Idda","Maria Laura","Institute for Genetic and Biomedical Research, National Research Council, Sassari, Italy",NA
"118","32973779","10.3389/fimmu.2020.01880","The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.","Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome infecting animals and humans. Coronaviruses have been described more than 70 years ago and contain many species. Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) are lethal species caused by human coronaviruses (HCoVs). Currently, a novel strain of HCoVs, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19). SARS-CoV-2 w","2020","10","14","Front Immunol","Frontiers in immunology","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); antibody dependent enhancement (ADE); clinical trial; coronavirus disease 2019 (Covid-19); pandemic; receptor binding domain (RBD); spike (S) protein; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, Viral; Antibody-Dependent Enhancement; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Evaluation; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Viral Vaccines","Alturki","Sana O","Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States",NA
"119","32973505","10.3389/fphar.2020.01258","Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19.","As the COVID-19 is still growing throughout the globe, a thorough investigation into the specific immunopathology of SARS-CoV-2, its interaction with the host immune system and pathogen evasion mechanism may provide a clear picture of how the pathogen can breach the host immune defenses in elderly patients and patients with comorbid conditions. Such studies will also reveal the underlying mechanism of how children and young patients can withstand the disease better. The study of the immune defen","2020","10","06","Front Pharmacol","Frontiers in pharmacology","COVID-19; SARS-CoV-2; antiviral treatment; coronavirus; repurposed drug; vaccine development","Saha","Rudra P","Department of Biotechnology, School of Life Science &amp",NA
"120","32969973","10.1097/COH.0000000000000648","Coronavirus disease-19 vaccine development utilizing promising technology.","Coronavirus disease-19 (COVID-19) is a highly transmittable and pathogenic pneumonia-causing disease, which is caused by severe acute respiratory syndrome coronavirus-2, resulting in millions of deaths globally. Severe acute respiratory syndrome coronavirus-2 may coexist with human populations for a long time. Therefore, high-effective COVID-19 vaccines are an urgent need. Vaccines help in the development of long-lasting humoral or cellular immunity, or both, by exposing individuals to antigens ","2020","10","13","Curr Opin HIV AIDS","Current opinion in HIV and AIDS","Adenoviridae; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Vaccination; Vaccines, Attenuated; Vaccines, DNA; Vaccines, Inactivated; Vaccines, Synthetic; Viral Vaccines","Wang","Yihan","Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin",NA
"121","32969369","10.33314/jnhrc.v18i2.2806","Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), a respiratory illness. COVID-19 has now become a global public health crisis causing alarming numbers of morbidity and mortality. Ever since the COVID-19 pandemic started scientists, researchers, universities, companies, and institutions all around the world have been endeavoring to discover a potential treatment for COVID-19. Numerous studies and clinical tr","2020","10","01","J Nepal Health Res Counc","Journal of Nepal Health Research Council","Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Gyanwali","Pradip","Nepal Health Research Council, Ramshah Path, Kathmandu, Nepal",NA
"122","32967006","10.1038/s41586-020-2798-3","SARS-CoV-2 vaccines in development.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: ","2020","10","29","Nature","Nature","Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Drug Industry; Humans; Immunity, Mucosal; Pandemics; Pneumonia, Viral; Viral Vaccines","Krammer","Florian","Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm","florian.krammer@mssm.edu"
"123","32966315","10.1371/journal.pone.0239385","Multiple drivers of the COVID-19 spread: The roles of climate, international mobility, and region-specific conditions.","Following its initial appearance in December 2019, coronavirus disease 2019 (COVID-19) quickly spread around the globe. Here, we evaluated the role of climate (temperature and precipitation), region-specific COVID-19 susceptibility (BCG vaccination factors, malaria incidence, and percentage of the population aged over 65 years), and human mobility (relative amounts of international visitors) in shaping the geographical patterns of COVID-19 case numbers across 1,020 countries/regions, and examine","2020","10","13","PLoS One","PloS one","Betacoronavirus; COVID-19; Climate; Communicable Diseases, Imported; Coronavirus Infections; Disease Susceptibility; Humans; Pandemics; Pneumonia, Viral; Regression Analysis; SARS-CoV-2; Travel-Related Illness","Kubota","Yasuhiro","Faculty of Science, University of the Ryukyus, Okinawa, Japan",NA
"124","32966155","10.1080/21645515.2020.1809267","Preparatory phase for clinical trials of COVID-19 vaccine in Nepal.","Public health data suggested a rapid rise in COVID-19-confirmed cases in Nepal along with increased deaths. There has been a wide variation in clinical outcomes of this disease. Control of this pandemic depends on the availability of vaccines or drugs for SARS-CoV-2. Thus, viral and human genetics/genomics and immunology are necessary to understand whether these factors will affect clinical trials of vaccines in Nepal.","2021","03","09","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","COVID-19; Nepal; asymptomatic infections; clinical manifestations; molecular diagnostics; vaccines; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Development; Humans; Nepal; Quarantine; Transients and Migrants","Gupta","Govind Prasad","Department of Clinical Microbiology, School of Physiotherapy and Paramedical Science, Lovely Professional University , Phagwara, India",NA
"125","32963672","10.11604/pamj.2020.36.206.23977","Expedited COVID-19 vaccine trials: a rat-race with challenges and ethical issues.","The intense global efforts are directed towards development of vaccines to halt the COVID-19 virus pandemic. There are 160 candidate vaccines under clinical trials across the world using different molecular targets and techniques. This race for the vaccine has several challenges and ethical issues like compressed timelines, generation and proper management of resources and finances, risks to the participating volunteers due to curtailed research trial processes, geopolitical contentions, misinfo","2020","09","30","Pan Afr Med J","The Pan African medical journal","COVID-19; ethics; vaccine; Betacoronavirus; Bioethical Issues; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Communication; Coronavirus Infections; Healthy Volunteers; Humans; Internationality; Pandemics; Pneumonia, Viral; Resource Allocation; SARS-CoV-2; Social Media; Time Factors; Viral Vaccines","Kamble","Prathamesh Haridas","Department of Physiology, All India Institute of Medical Sciences, Nagpur, India",NA
"126","32961897","10.3390/v12091039","Induction of the Antiviral Immune Response and Its Circumvention by Coronaviruses.","Some coronaviruses are zoonotic viruses of human and veterinary medical importance. The novel coronavirus, severe acute respiratory symptoms coronavirus 2 (SARS-CoV-2), associated with the current global pandemic, is characterized by pneumonia, lymphopenia, and a cytokine storm in humans that has caused catastrophic impacts on public health worldwide. Coronaviruses are known for their ability to evade innate immune surveillance exerted by the host during the early phase of infection. It is impor","2020","10","13","Viruses","Viruses","antiviral immune response; coronaviruses; immune evasion; interferon signaling; viral tissue tropism; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus; Coronavirus Infections; Cytokines; Immune Evasion; Immunity, Innate; Immunity, Mucosal; Pandemics; Pneumonia, Viral; SARS-CoV-2; Signal Transduction; Viral Tropism","Liu","Ping","Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou 350002, China",NA
"127","32961361","10.1016/j.cct.2020.106154","Data monitoring committees for clinical trials evaluating treatments of COVID-19.","The first cases of coronavirus disease 2019 (COVID-19) were reported in December 2019 and the outbreak of SARS-CoV-2 was declared a pandemic in March 2020 by the World Health Organization. This sparked a plethora of investigations into diagnostics and vaccination for SARS-CoV-2, as well as treatments for COVID-19. Since COVID-19 is a severe disease associated with a high mortality, clinical trials in this disease should be monitored by a data monitoring committee (DMC), also known as data safety","2020","12","11","Contemp Clin Trials","Contemporary clinical trials","Adverse events; Data safety monitoring boards; Pandemic; Randomized controlled trials; SARS-CoV-2; COVID-19; COVID-19 Testing; Clinical Trials Data Monitoring Committees; Computer Simulation; Ethics Committees, Research; Humans; Randomized Controlled Trials as Topic; Research Design; SARS-CoV-2; Vaccination","M..tze","Tobias","Statistical Methodology, Novartis Pharma AG, Basel, Switzerland",NA
"128","32959618","10.2991/jegh.k.200823.001","Epidemic Landscape and Forecasting of SARS-CoV-2 in India.","India was one of the countries to institute strict measures for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) control in the early phase. Since, then, the epidemic growth trajectory was slow before registering an explosion of cases due to local cluster transmissions. We estimated the growth rate and doubling time of SARS-CoV-2 for India and high burden states using crowdsourced time series data. Further, we also estimated the Basic Reproductive Number (R0) and Time-dependent Repro","2020","09","22","J Epidemiol Glob Health","Journal of epidemiology and global health","COVID-19; India; R0; Rt","Rajendrakumar","Aravind Lathika","School of Medicine, University of Dundee, UK",NA
"129","32958009","10.1186/s12967-020-02532-4","The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019.","More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in over 760,000 deaths worldwide so far. As a result, COVID-19 has changed all our lives as we battle to curtail the spread of the infection in the absence of specific therapies against coronaviruses and in anticipation of a proven safe and efficacious vaccine. Common with previous outbreaks of","2020","10","02","J Transl Med","Journal of translational medicine","Acute respiratory distress syndrome; COVID-19; Mesenchymal stromal cells; SARS-CoV-2; Animals; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Mesenchymal Stem Cell Transplantation; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Translational Medical Research","Canham","Maurice A","Tissues, Cells &amp","maurice.canham@nhs.scot"
"130","32957894","10.2174/1574891X15999200918144833","Understanding the Role of Corona Virus based on Current Scientific Evidence - A Review with Emerging Importance in Pandemic.","Coronavirus disease is a potentially deadly disease and of significant apprehension for global communal health because of its lethality. Vaccines and antiviral medications are still under trial to prevent or treat human coronavirus (HCoV) till date. The virus HCoV originated in 2003, SARS-CoV, which causes respiratory syndrome having distinctive pathogenesis and infections of the respiratory tract. A mechanism was projected for the evolution of SARS virus, and a handy association with bats was f","2021","01","14","Recent Pat Antiinfect Drug Discov","Recent patents on anti-infective drug discovery","COVID-19; angiotensin-converting enzyme 2; antiviralmedications; health care; pandemic; transmission; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Antiviral Agents; COVID-19; COVID-19 Vaccines; Evidence-Based Medicine; Humans; SARS-CoV-2","Ray","Suman K","Independent Researcher, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh 462020, India",NA
"131","32955770","10.1111/acel.13237","Cellular senescence as a potential mediator of COVID-19 severity in the elderly.","SARS-CoV-2 is a novel betacoronavirus which infects the lower respiratory tract and can cause coronavirus disease 2019 (COVID-19), a complex respiratory distress syndrome. Epidemiological data show that COVID-19..has a rising mortality particularly in individuals with advanced age. Identifying a functional association between SARS-CoV-2 infection and the process of biological aging may provide a tractable avenue for therapy to prevent acute and long-term disease. Here, we discuss how cellular se","2020","11","04","Aging Cell","Aging cell","Age Factors; Aged; Aging; Betacoronavirus; Biomarkers; COVID-19; Cellular Senescence; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index","Nehme","Jamil","European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG), University of Groningen (RUG, Groningen NL, The Netherlands",NA
"132","32948465","10.1016/j.transci.2020.102934","An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research.","This communication provides a compilation on aspects of COVID-19 infection control measures, describes the potential role of therapeutic plasma exchange to reduce fatality rates, addresses precautions concerning dexamethasone pharmacotherapy and updates the current status on the availability of vaccines. As part of passive immunotherapy, it focuses on various blood derivatives. These include coronavirus neutralising antibodies extracted from different sources to be administered as a pure hyper c","2020","12","04","Transfus Apher Sci","Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis","COVID-19 convalescent plasma; Corticosteroids; Hyperimmune NAb for passive immunization; Therapeutic plasma exchange; Vaccine; Adrenal Cortex Hormones; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Immunization, Passive; SARS-CoV-2","Putter","Jeffrey S","Medical Biomechanics Inc., 100 E. San Marcos Blvd., #400, San Marcos, North San Diego County), CA 92069, United States. Electronic address: Jputter@LTSP","Jputter@LTSP.com"
"133","32946131","10.1002/rmv.2158","Investigation of immune cells on elimination of pulmonary-Infected COVID-19 and important role of innate immunity, phagocytes.","We identified types of immune cells that contribute to clearing COVID-19 during the acute phase of the infection in mouse model and human. Our results suggest that both innate and adaptive immune responses are essential for controlling COVID-19 infection. Mild infection report of children by COVID-19 comparing adults' infection causes conclusion of higher resistance of immune system of children comparing adults. Our results show innate immune system including phagocytes contribute severely to th","2020","10","09","Rev Med Virol","Reviews in medical virology",NA,"Farshi","Esmaeil","R&amp",NA
"134","32945335","10.1093/cid/ciaa1425","Warp Speed for COVID-19 Vaccines: Why are Children Stuck in Neutral?","While adult clinical trials of COVID-19 vaccines have moved quickly into Phase 3 clinical trials, clinical trials have not started in children in the US. The direct COVID-19 impact upon children is greater than that observed for a number of other pathogens for which we now have effective pediatric vaccines. Additionally, the role of children in SARS-CoV-2 transmission has clearly been underappreciated. Carefully conducted Phase II clinical trials can adequately address potential COVID-19 vaccine","2020","10","09","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","SARS-CoV-2; immunization; immunize; pediatric; vaccination","Anderson","Evan J","Department of Pediatrics, Emory University School of Medicine, Atlanta, GA",NA
"135","32943115","10.1186/s13063-020-04714-3","Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.","The Bacille Calmette-Gu..rin (BCG) vaccine against tuberculosis is associated with non- specific protective effects against other infections, and significant reductions in all-cause morbidity and mortality have been reported. We aim to test whether BCG vaccination may reduce susceptibility to and/or the severity of COVID-19 and other infectious diseases in health care workers (HCW) and thus prevent work absenteeism.The primary objective is to reduce absenteeism due to illness among HCW during th","2020","09","23","Trials","Trials","BCG vaccine; COVID-19; Health care workers; Heterologous effects of vaccines; NSEs/Non-specific effects of vaccines; Pandemic Immune training.; Protocol; Randomised controlled trial; Absenteeism; BCG Vaccine; Betacoronavirus; COVID-19; Coronavirus Infections; Denmark; Female; Health Personnel; Humans; Male; Multicenter Studies as Topic; Occupational Health; Pandemics; Patient Admission; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Sick Leave; Single-Blind Method; Time Factors; Treatment Outcome; Vaccination","Madsen","Anne Marie Rosendahl","Bandim Health Project, OPEN, Department of Clinical Research, University of Southern Denmark/Odense University Hospital, Odense, Denmark. arosendahl@health.sdu","arosendahl@health.sdu.dk"
"136","32941801","10.1016/j.cell.2020.08.051","Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly.","BCG vaccination in children protects against heterologous infections and improves survival independently of tuberculosis prevention. The phase III ACTIVATE trial assessed whether BCG has similar effects in the elderly. In this double-blind, randomized trial, elderly patients (n..= 198) received BCG or placebo vaccine at hospital discharge and were followed for 12..months for new infections. At interim analysis, BCG vaccination significantly increased the time to first infection (median 16..weeks","2020","10","26","Cell","Cell","BCG; cytokines; elderly; epigenetic modifications; infection incidence; respiratory infections; trained immunity; vaccination; Aged; Aged, 80 and over; BCG Vaccine; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Respiratory Tract Infections; Virus Diseases","Giamarellos-Bourboulis","Evangelos J","(th) Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 124 62 Athens, Greece. Electronic address: egiamarel@med.uoa","egiamarel@med.uoa.gr"
"137","32940090","10.1080/14760584.2020.1825951","Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations.","Introduction Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has quickly spread around the world. Areas covered This review will discuss the available immunologic and clinical evidence to support the benefit of the influenza, pneumococcal, and tuberculosis vaccines in the context of COVID-19 as well as to provide an overview on the COVID-19-specific vaccines that are in the development pipeline. In addition, implications for vac","2020","12","21","Expert Rev Vaccines","Expert review of vaccines","BCG vaccine; COVID-19; influenza vaccine; pneumococcal vaccine; vaccination campaign; vaccines; vaccinovigilance; COVID-19; COVID-19 Vaccines; Drug Development; Humans; Pharmacovigilance; Public Health; SARS-CoV-2; Vaccination","Sultana","Janet","Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina , Messina, Italy",NA
"138","32938370","10.1186/s12859-020-03648-6","A computational framework for modeling and studying pertussis epidemiology and vaccination.","Emerging and re-emerging infectious diseases such as Zika, SARS, ncovid19 and Pertussis, pose a compelling challenge for epidemiologists due to their significant impact on global public health. In this context, computational models and computer simulations are one of the available research tools that epidemiologists can exploit to better understand the spreading characteristics of these diseases and to decide on vaccination policies, human interaction controls, and other social measures to count","2020","10","21","BMC Bioinformatics","BMC bioinformatics","Colored Petri Nets; Computational models; Epidemiological model; Pertussis; Adolescent; Child; Computational Biology; Computer Simulation; Humans; Reproducibility of Results; Vaccination; Whooping Cough","Castagno","Paolo","Department of Computer Science, University of Turin, Turin, Italy",NA
"139","32936776","10.2196/22596","Associations of Mental Health and Personal Preventive Measure Compliance With Exposure to COVID-19 Information During Work Resumption Following the COVID-19 Outbreak in China: Cross-Sectional Survey Study.","Risk and crisis communication plays an essential role in public health emergency responses. The COVID-19 pandemic has triggered spontaneous and intensive media attention, which has affected people's adoption of personal preventive measures and their mental health. The aim of this study was to investigate the associations between exposure to COVID-19-specific information and mental health (depression and sleep quality) and self-reported compliance with personal preventive measures (face mask wear","2020","10","16","J Med Internet Res","Journal of medical Internet research","COVID-19; China; communication; cross-sectional; information exposure; mental health; personal preventive measures; prevention; public health; risk; Adolescent; Adult; Betacoronavirus; COVID-19; China; Coronavirus Infections; Cross-Sectional Studies; Depression; Disease Outbreaks; Female; Hand Disinfection; Health Risk Behaviors; Humans; Male; Mental Health; Pandemics; Pneumonia, Viral; SARS-CoV-2; Self Report; Surveys and Questionnaires; Treatment Adherence and Compliance; Young Adult","Pan","Yihang","Precision Medicine Center, Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China",NA
"140","32935536","10.37201/req/086.2020","[Immunity against SARS-CoV-2: walking to the vaccination].","The coronavirus are a wide group of viruses among that the SARS-CoV-2 is included (family Coronaviridae, subfamily Coronavirinae, genus Betacoronavirus and subgenus Sarbecovirus). Its main structural proteins are the membrane (M), the envelope (E), the nucleocapsid (N) and spike (S). The immune response to SARS-CoV-2 involves the cellular and the humoral sides, with neutralizing antibodies fundamentally directed against the S antigen. Although the seroprevalence data are frequently assumed as pr","2020","12","10","Rev Esp Quimioter","Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","SARS-CoV2; immunity; vaccination; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Cross Reactions; Humans; Immunity, Herd; Immunization; Neutralization Tests; Pandemics; SARS-CoV-2; Spain; Vaccination; Viral Structural Proteins","Rodr..guez Hern..ndez","C","Juan Carlos Sanz Moreno, Unidad de Microbiolog..a Cl..nica. Laboratorio Regional de Salud P..blica de la Comunidad de Madrid. Direcci..n General de Salud P..blica de la Comunidad de Madrid. Centro de Especialidades M..dicas Vicente Soldevilla 2.. planta. C/ Sierra de Alquife 8. Madrid 28053 Spain. juan.sanz@salud.madrid",NA
"141","32935331","10.1111/cei.13517","Vaccines for COVID-19.","Since the emergence of COVID-19, caused by the SARS-CoV-2 virus at the end of 2019, there has been an explosion of vaccine development. By 24 September 2020, a staggering number of vaccines (more than 200) had started preclinical development, of which 43 had entered clinical trials, including some approaches that have not previously been licensed for human vaccines. Vaccines have been widely considered as part of the exit strategy to enable the return to previous patterns of working, schooling a","2020","11","13","Clin Exp Immunol","Clinical and experimental immunology","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vaccination; Viral Vaccines","Tregoning","J S","Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK",NA
"142","32934758","10.1155/2020/1401053","Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes.","The threat of contagious infectious diseases is constantly evolving as demographic explosion, travel globalization, and changes in human lifestyle increase the risk of spreading pathogens, leading to accelerated changes in disease landscape. Of particular interest is the aftermath of superimposing viral epidemics (especially SARS-CoV-2) over long-standing diseases, such as tuberculosis (TB), which remains a significant disease for public health worldwide and especially in emerging economies. The","2020","09","24","Can Respir J","Canadian respiratory journal","BCG Vaccine; Betacoronavirus; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Coinfection; Coronavirus Infections; Cytokines; Diagnostic Errors; Disease Outbreaks; Humans; Influenza, Human; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; SARS Virus; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severity of Illness Index; Tuberculosis","Crisan-Dabija","Radu","University of Medicine and Pharmacy &quot",NA
"143","32934375","10.1038/d41586-020-02619-4","Researchers highlight 'questionable' data in Russian coronavirus vaccine trial results.",NA,"2020","09","28","Nature","Nature","SARS-CoV-2; Vaccines","Abbott","Alison",NA,NA
"144","32933536","10.1186/s12967-020-02520-8","Pathophysiology and treatment strategies for COVID-19.","The outbreak of Coronavirus disease of 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has posed a serious health threat. The increasing number of COVID-19 cases around the world is overwhelming hospitals and pushing the global death toll to over 746,000, which has pushed the sprint to find new treatment options. In this article, we reviewed the SARS-CoV-2 pathophysiology, transmission, and potential treatment strategies.","2020","10","02","J Transl Med","Journal of translational medicine","2019 novel coronavirus; ACE-2 receptor; Pandemic; Receptor binding protein; SARS-CoV-2; Viral inhibitor; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Disease Susceptibility; Humans; Models, Biological; Pandemics; Pneumonia, Viral; SARS-CoV-2; Translational Medical Research; Viral Vaccines","Kumar","Manoj","Research Department, Sidra Medicine, Doha, Qatar",NA
"145","32929259","10.1038/d41586-020-02633-6","Scientists relieved as coronavirus vaccine trial restarts - but question lack of transparency.",NA,"2020","09","23","Nature","Nature","Politics; Research data; SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Confidentiality; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Time Factors; Trust; United Kingdom; Viral Vaccines","Cyranoski","David",NA,NA
"146","32926920","10.1016/j.lfs.2020.118421","New insights on possible vaccine development against SARS-CoV-2.","In December 2019, a novel virus, namely COVID-19 caused by SARS-CoV-2, developed from Wuhan, (Hubei territory of China) used its viral spike glycoprotein receptor-binding domain (RBD) for the entrance into a host cell by binding with ACE-2 receptor and cause acute respiratory distress syndrome (ARDS). Data revealed that the newly emerged SARS-CoV-2 affected more than 24,854,140 people with 838,924 deaths worldwide. Until now, no licensed immunization or drugs are present for the medication of SA","2020","11","09","Life Sci","Life sciences","Immune response; Inactivated virus vaccine; Neutralization; Protein-based vaccine; SARS-CoV-2; Spike protein; Antibodies, Viral; Antigens, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Epitopes; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Envelope Proteins; Viral Vaccines","Chaudhry","Sundas Nasir","Department of Biochemistry, Faculty of Sciences, University of Agriculture, Faisalabad 38000, Pakistan",NA
"147","32926660","10.1177/0192623320959090","Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).","The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an urgent need to develop safe and efficacious vaccines. The scientific community has made tremendous efforts to understand the disease, and unparalleled efforts are ongoing to develop vaccines and treatments. Toxicologists and pathologists are involved in these efforts to test the efficacy and safety of vaccine candidates. Pr","2020","12","09","Toxicol Pathol","Toxicologic pathology","COVID-19; SARS-CoV-2; accelerated vaccine development; coronavirus; coronavirus diseases; vaccine efficacy; vaccine safety; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; Humans; SARS-CoV-2; Time Factors; Viral Vaccines","Bennet","Bindu M","1444Voyager Therapeutics, Cambridge, MA, USA",NA
"148","32926453","10.1002/jmv.26512","Methotrexate inhibits SARS-CoV-2 virus replication &quot;in vitro&quot;.","In early 2020 the new respiratory syndrome COVID-19 (caused by the zoonotic SARS-CoV-2 virus) spread like a pandemic, starting from Wuhan, China, causing severe economic depression. Despite some advances in drug treatments of medical complications in the later stages of the disease, the pandemic's death toll is tragic, as..no vaccine or specific antiviral treatment is currently available. By using a systems approach, we identify the host-encoded pathway, which provides ribonucleotides to viral R","2021","03","08","J Med Virol","Journal of medical virology","COVID-19; drug repurposing; methotrexate; purine biosynthesis inhibition; Animals; Antiviral Agents; COVID-19; Cell Line; Chlorocebus aethiops; Methotrexate; Pandemics; RNA, Viral; SARS-CoV-2; Vero Cells; Virus Replication","Caruso","Arnaldo","Department of Molecular and Translational Medicine, Section of Microbiology and Virology, University of Brescia Medical School, Brescia, Italy",NA
"149","32920170","10.1016/j.biochi.2020.09.003","May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients?","In around 10% of SARS-CoV-2 infected patients, coronavirus disease-2019 (Covid-19) symptoms are complicated with a severe lung damage called Acute Respiratory Distress Syndrome (ARDS), which is often lethal. ARDS is mainly associated with an uncontrolled overproduction of immune cells and cytokines, called &quot;cytokine storm syndrome&quot;; it appears 7-15 days following the onset of symptoms, leading to systemic inflammation and multiple organ failure. Because they are well-known metabolic pr","2020","12","07","Biochimie","Biochimie","Docosopentaenoic acid; Eicosapentaenoic acid; Immunity; Lipid; Virus; ..-linolenic acid; Animals; COVID-19; Clinical Trials as Topic; Dietary Supplements; Fatty Acids, Omega-3; Humans","Weill","Pierre","Bleu-Blanc-C..ur Association - Univ Rennes, France",NA
"150","32918548","10.1093/jpids/piaa115","Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.","Although coronavirus disease 2019 (COVID-19) is a mild infection in most children, a small proportion develop severe or critical illness. Data describing agents with potential antiviral activity continue to expand such that updated guidance is needed regarding use of these agents in children. A panel of pediatric infectious diseases physicians and pharmacists from 20 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set ","2021","02","25","J Pediatric Infect Dis Soc","Journal of the Pediatric Infectious Diseases Society","COVID-19; SARS-CoV-2; antiviral; pediatric; Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; Child; Evidence-Based Medicine; Humans; Immunocompromised Host; Risk Factors; Severity of Illness Index; Systemic Inflammatory Response Syndrome","Chiotos","Kathleen","Division of Critical Care Medicine, Department of Anesthesia and Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA",NA
"151","32918053","10.1038/d41586-020-02523-x","China's coronavirus vaccine shows military's growing role in medical research.",NA,"2020","09","28","Nature","Nature","Medical research; Policy; Vaccines; Adenoviridae; Adolescent; Betacoronavirus; Biomedical Research; COVID-19; COVID-19 Vaccines; China; Coronavirus Infections; Humans; Military Personnel; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Viral Vaccines","Lewis","Dyani",NA,NA
"152","32915657","10.1080/17460441.2020.1820983","Are open-source approaches the most efficient way forward for COVID-19 drug discovery?","Introduction: The COVID-19 pandemic has catalyzed the production of potential antivirals and vaccines from research organizations across the globe. The initial step for all drug discovery models is the identification of suitable targets. One approach organizations may take to tackle this involves issuing raw data publicly for collaboration with other organizations in order to spark discussion, collectively experiment and stay up to date with advances in scientific knowledge. Areas cove","2021","02","12","Expert Opin Drug Discov","Expert opinion on drug discovery","COVID-19; antiviral; coronavirus; treatment; Antiviral Agents; COVID-19; Clinical Trials as Topic; Drug Discovery; Humans; International Cooperation; SARS-CoV-2; Viral Vaccines","Harky","Amer","Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital , Liverpool, UK",NA
"153","32913364","10.1371/journal.ppat.1008796","A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients.","There is an urgent need for effective treatment and preventive vaccine to contain this devastating global pandemic, which requires a comprehensive understanding of humoral responses specific to SARS-CoV-2 during the disease progression and convalescent phase of COVID-19 patients. We continuously monitored the serum IgM and IgG responses specific to four SARS-CoV-2 related antigens, including the nucleoprotein (NP), receptor binding domain (RBD), S1 protein, and ectodomain (ECD) of the spike prot","2020","09","23","PLoS Pathog","PLoS pathogens","Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Immunoglobulin G; Longitudinal Studies; Pandemics; Pneumonia, Viral; SARS-CoV-2; Serologic Tests; Spike Glycoprotein, Coronavirus","Chen","Yuxin","Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China",NA
"154","32912808","10.1016/j.pec.2020.09.002","Public awareness in Egypt about COVID-19 spread in the early phase of the pandemic.","This study aimed to evaluate public awareness in Egypt related to the coronavirus. An online structured survey was conducted during March and April 2020 to assess coronavirus knowledge. The questionnaire was divided into 6 parts consisting of 39 questions for a total possible score of 0 to 39; to assess the participants' general knowledge [10 items]; symptoms knowledge [2 items]; transmission knowledge [6 items]; preventive knowledge [4 items]; treatment knowledge [6 items], and public knowledge","2021","01","29","Patient Educ Couns","Patient education and counseling","COVID-19; Egypt; Public awareness; WHO","Elgendy","Marwa O","Department of Clinical Pharmacy, Teaching Hospital of Faculty of Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt",NA
"155","32908297","10.1038/d41586-020-02583-z","The underdog coronavirus vaccines that the world will need if front runners stumble.",NA,"2020","09","23","Nature","Nature","Diseases; SARS-CoV-2; Vaccines; Virology; Adenoviridae; Administration, Intranasal; Animals; Biotechnology; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Disease Models, Animal; Drug Industry; Humans; Immunity, Mucosal; Influenza Vaccines; Mice; Pandemics; Pneumonia, Viral; Treatment Outcome; Uncertainty; Viral Vaccines","Callaway","Ewen",NA,NA
"156","32908295","10.1038/d41586-020-02594-w","A leading coronavirus vaccine trial is on hold: scientists react.",NA,"2020","09","10","Nature","Nature","Diseases; SARS-CoV-2; Vaccines","Phillips","Nicky",NA,NA
"157","32907856","10.1136/bmj.m3525","Covid-19: Oxford researchers halt vaccine trial while adverse reaction is investigated.",NA,"2020","09","10","BMJ","BMJ (Clinical research ed.)",NA,"Mahase","Elisabeth","The BMJ",NA
"158","32907286","10.3760/cma.j.cn112150-20200427-00653","[Exploration and application of a novel attempt to recruit participants in clinical trials of vaccines under the emergency].","Objective: To evaluate and share the novel method for recruiting participants in clinical trials of vaccines in emergency situations. Methods: To publish recruitment notice in local areas of Wuhan through websites and medium, and guide interested persons to log in to the&quot;Clinical Trials of SARS-CoV-2 Vaccine Reservation and Health Declaration System&quot;to appoint and register their health information. The &quot;Health Declaration System&quot; provides each volunteer evaluation and risk le","2020","09","15","Zhonghua Yu Fang Yi Xue Za Zhi","Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]","Clinical trial; Health declaration; Recruitment system; Telephone interviews; Vaccines; Adult; COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Coronavirus Infections; Emergencies; Female; Humans; Male; Pandemics; Patient Selection; Pneumonia, Viral; Viral Vaccines; Volunteers; Young Adult","Jiang","H D C","School of Public Health, Southeast University, Nanjing 210009, China",NA
"159","32907278","10.3760/cma.j.cn112150-20200803-01084","[Conduct vaccines clinical trials and optimize the immunization strategies].","Development of an effective vaccine requires a long and complicated process. Preclinical studies and phase ..., ..., ... clinical trials mainly focused on the assessment of the vaccine's safety (tolerability), immunogenicity and efficacy before license. After license, it is necessary to further evaluate the actual effectiveness and safety in the general population through phase ... clinical trials and optimize the immunization strategies with the disease's epidemiology data. In this special issu","2020","09","15","Zhonghua Yu Fang Yi Xue Za Zhi","Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]","Clinical trials; Immunization strategies; Vaccines; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunization; Pandemics; Pneumonia, Viral; Vaccines; Viral Vaccines","Yin","Z D","National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China",NA
"160","32905186","10.1007/s13337-020-00628-5","A brief outline of respiratory viral disease outbreaks: 1889-till date on the public health perspectives.","Severe acute respiratory syndrome coronavirus 2..(SARS-CoV-2)..is currently causing the respiratory illness termed as the coronavirus disease 2019 or the COVID-19 pandemic...Indeed, the significant increase in deaths in the current days due to influenza around the world started in 1889 is a continued public health threat because of its intermittent style of pandemic outbreaks. An array of research on the influenza viruses has been conducted especially pointing on (1) the development of the anti-","2020","09","28","Virusdisease","Virusdisease","COVID-19; History; Influenza viruses; Pandemic; Public health","Noor","Rashed","Department of Microbiology, School of Environment and Life Sciences (SELS), Independent University, Bangladesh (IUB), Plot 16, Block B, Aftabuddin Ahmed Road, Bashundhara, Dhaka, 1229 Bangladesh",NA
"161","32905011","10.1016/j.ajps.2020.08.001","SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies.","The development of a massively producible vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, is essential for stopping the current coronavirus disease (COVID-19) pandemic. A vaccine must stimulate effective antibody and T cell responses in vivo to induce long-term protection. Scientific researchers have been developing vaccine candidates for the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) since the ou","2020","09","28","Asian J Pharm Sci","Asian journal of pharmaceutical sciences","Biomimetic nanotechnology; COVID-19; SARS-CoV-2; Vaccine; Virus-like nanoparticles","Huang","Lanxiang","Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China",NA
"162","32903199","10.2196/23543","Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study.","The COVID-19 pandemic is expected to cause significant morbidity and mortality. The development of an effective vaccine will take several months to become available, and its affordability is unpredictable. Transfusion of convalescent plasma (CP) may provide passive immunity. Based on initial data from China, a group of hematologists, infectious disease specialists, and intensivists drafted this protocol in March 2020. The aim of this study is to test the feasibility, safety, and efficacy of CP i","2020","10","23","JMIR Res Protoc","JMIR research protocols","COVID-19; SARS-CoV-2; antibodies; convalescent plasma; coronaviruses; efficacy; feasibility; immunology; infectious disease; safety; treatment","Albalawi","Mohammed","Department of Internal Medicine, College of Medicine, Taibah University, Madinah, Saudi Arabia",NA
"163","32902818","10.1007/s11357-020-00261-6","A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin.","We are in the midst of the global pandemic. Though acute respiratory coronavirus (SARS-COV2) that leads to COVID-19 infects people of all ages, severe symptoms and mortality occur disproportionately in older adults. Geroscience interventions that target biological aging could decrease risk across multiple age-related diseases and improve outcomes in response to infectious disease. This offers hope for a new host-directed therapeutic approach that could (i) improve outcomes following exposure or ","2021","01","27","Geroscience","GeroScience","Aging; COVID-19; Geroscience; Immunity; Metformin","Justice","Jamie N","Sticht Center for Healthy Aging and Alzheimer's Prevention, Internal Medicine - Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA. jnjustic@wakehealth","jnjustic@wakehealth.edu"
"164","32901559","10.12968/bjon.2020.29.16.948","In search of a vaccine against COVID-19: implications for nursing practice.","This article discusses the background to the current COVID-19 pandemic. The specific features of the causative pathogen (SARS-CoV-2) are outlined, together with a 'whistlestop' revision of immunological principles. The article goes on to discuss the principles and mechanisms of immunisation and the stages of vaccine development. The current situation in relation to the race to develop a vaccine against COVID-19 is incorporated and the immunological principles being adapted by the top contenders ","2020","09","10","Br J Nurs","British journal of nursing (Mark Allen Publishing)","COVID-19; Coronavirus; Genome; Nursing in a pandemic; SARS-CoV-2; Vaccine; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Viral Vaccines","Boulton","Jacqueline","Lecturer in Nursing Education/International Strategy Lead for Student Mobility and Global Health, Florence Nightingale Faculty of Nursing, Midwifery &amp",NA
"165","32900341","10.2174/0929867327666200908113642","Current Scenario and Future Prospect in the Management of COVID-19.","The COVID-19 pandemic continues to wreak havoc worldwide due to the lack of risk assessment, rapid spreading ability, and propensity to precipitate severe disease in comorbid conditions. In an attempt to fulfill the demand for prophylactic and treatment measures to intercept the ongoing outbreak, the drug development process is facing several obstacles and renaissance in clinical trials, including vaccines, antivirals, immunomodulators, plasma therapy, and traditional medicines. This review outl","2021","01","11","Curr Med Chem","Current medicinal chemistry","COVID-19; Convalescent Plasma; Cytokine Storm; Remdesivir; SARS-CoV-2; TCM; Vaccines; Antiviral Agents; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Immunization, Passive; Immunologic Factors; Medicine, Traditional; Pandemics","Borah","Pobitra","Pratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati-781026, Assam, India",NA
"166","32898468","10.1098/rsob.200174","Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy.","The world is passing through a very difficult phase due to the coronavirus disease 2019 (COVID-19) pandemic, which has disrupted almost all spheres of life. Globally, according to the latest World Health Organization report (10 August 2020), COVID-19 has affected nearly 20 million lives, causing 728 013 deaths. Due to the lack of specific therapeutic drugs and vaccines, the outbreak of disease has spawned a corpus of contagious infection all over the world, day by day, without control. As the se","2020","09","16","Open Biol","Open biology","COVID-19; SARS-CoV-2; chloroquine; plasma therapy; viraemia; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunization, Passive; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index","Piyush","Ravikant","School of Biotechnology, Madurai Kamaraj University, Madurai, Tamil Nadu 625021, India",NA
"167","32897660","10.1056/NEJMp2025331","&quot;When Will <i>We</i> Have a Vaccine?&quot; - Understanding Questions and Answers about Covid-19 Vaccination.",NA,"2020","12","11","N Engl J Med","The New England journal of medicine","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; Pandemics; United States; United States Food and Drug Administration","Bloom","Barry R","From the Harvard T.H. Chan School of Public Health, Boston (B.R.B.), the University of Georgia Grady College of Journalism and Mass Communication, Athens (G.J.N.), and the Emory Vaccine Center, Emory University School of Medicine, Atlanta (W",NA
"168","32897039","10.1097/PTS.0000000000000755","Returning to Elective Orthopedic Surgery During the COVID-19 Pandemic: A Multidisciplinary and Pragmatic Strategy for Initial Patient Selection.","The aim of the study was to design an objective, transparent, pragmatic, and flexible workflow to assist with patient selection during the initial phase of return to elective orthopedic surgery during the COVID-19 pandemic with the main purpose of enhancing patient safety. A multidisciplinary working group was formed consisting of representatives for orthopedics, epidemiology, ethics, infectious diseases, cardiovascular diseases, and intensive care medicine. Preparation for upcoming meetings con","2020","12","01","J Patient Saf","Journal of patient safety","Betacoronavirus; COVID-19; Coronavirus Infections; Elective Surgical Procedures; Humans; Interdisciplinary Communication; Orthopedic Procedures; Pandemics; Patient Selection; Pneumonia, Viral; SARS-CoV-2","Vles","Georges F","Department of Safety Evaluation and Risk Management, Epidemiology, GlaxoSmithKline Vaccines, Siena, Italy",NA
"169","32896291","10.1016/S0140-6736(20)31866-3","Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.","We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S). We aimed to assess the safety and immunogenicity of two formulations (frozen and lyophilised) of this vaccine. We did two open, non-randomised phase 1/2 studies at two hospitals in Russia. We enrol","2020","10","05","Lancet","Lancet (London, England)","Adenoviridae; Adult; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Female; Humans; Immunity, Cellular; Immunity, Humoral; Immunization, Secondary; Immunoglobulin G; Injections, Intramuscular; Male; Pandemics; Pneumonia, Viral; Russia; SARS-CoV-2; Viral Vaccines; Young Adult","Logunov","Denis Y","Federal State Budget Institution &quot","ldenisy@gmail.com"
"170","32896275","10.1016/S2213-2600(20)30401-X","COVID-19 vaccine trials in Africa.",NA,"2020","11","16","Lancet Respir Med","The Lancet. Respiratory medicine","Africa; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Makoni","Munyaradzi",NA,NA
"171","32896274","10.1016/S2213-2600(20)30402-1","The Russian vaccine for COVID-19.",NA,"2020","11","16","Lancet Respir Med","The Lancet. Respiratory medicine","Adenoviridae; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Russia; SARS-CoV-2; Viral Vaccines","Burki","Talha Khan",NA,NA
"172","32894568","10.26355/eurrev_202008_22660","Three critical clinicobiological phases of the human SARS-associated coronavirus infections.","COVID-19 immune syndrome is a multi-systemic disorder induced by the COVID-19 infection. Pathobiological transitions and clinical stages of the COVID-19 syndrome following the attack of SARS-CoV-2 on the human body have not been fully explored. The aim of this review is to outline the three critical prominent phase regarding the clinicogenomics course of the COVID-19 immune syndrome. In the clinical setting, the COVID-19 process presents as &quot;asymptomatic/pre-symptomatic phase&quot;, &quot;r","2020","09","16","Eur Rev Med Pharmacol Sci","European review for medical and pharmacological sciences","Angiotensin-Converting Enzyme 2; Asymptomatic Diseases; Betacoronavirus; COVID-19; Coronavirus Infections; Cytokines; ErbB Receptors; Gene Expression Regulation; Humans; Immune System; Multiple Organ Failure; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Prognosis; Receptor, IGF Type 2; SARS-CoV-2; Sepsis; Severity of Illness Index; Spike Glycoprotein, Coronavirus","Turk","C","Department of Medical Microbiology, Lokman Hekim University, Ankara, Turkey. umitmalkan@hotmail","umitmalkan@hotmail.com"
"173","32893036","10.1016/j.vaccine.2020.08.059","Pregnant women's perceptions of risks and benefits when considering participation in vaccine trials.","Despite historical exclusion, there has been recent recognition of the need to address the health of pregnant women in research on vaccines against emerging pathogens. However, pregnant women's views and decision-making processes about vaccine research participation during infectious disease outbreaks remain underexplored. This study aims to examine women's decision-making processes around vaccine research participation during infectious disease outbreaks. We conducted qualitative semi-structure","2020","10","19","Vaccine","Vaccine","Decision-making; Pregnancy; Vaccine research; Zika vaccines; Adult; Clinical Trials as Topic; Decision Making; Female; Humans; Interviews as Topic; Patient Acceptance of Health Care; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Risk Assessment; Vaccination; Vaccines; Viral Vaccines; Zika Virus Infection","Jaffe","Elana","Center for Bioethics and Department of Social Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States",NA
"174","32888871","10.1016/j.jiph.2020.08.001","From SARS to COVID-19: What lessons have we learned?","After the outbreak of severe acute respiratory syndrome (SARS) in November 2002, coronaviruses (CoVs) received worldwide attention. On December 1, 2019, the first case of coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), was reported in Wuhan, China, and CoVs returned to public view. On January 30, 2020, the World Health Organization (WHO) declared that the COVID-19 epidemic is a public health emergency of international concern (PHEIC), and on March 11, 2020, the W","2020","11","16","J Infect Public Health","Journal of infection and public health","Chinese experience; Coronavirus disease 2019 (COVID-19); Pandemic; SARS; SARS-CoV-2; Betacoronavirus; COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Coronavirus Infections; Humans; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Public Health; SARS Virus; SARS-CoV-2; Severe Acute Respiratory Syndrome; Viral Vaccines; World Health Organization","Liu","Qin","Department of Oral Medicine, Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, China",NA
"175","32887954","10.1038/s41577-020-00434-6","Immunological considerations for COVID-19 vaccine strategies.","The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine str","2020","10","06","Nat Rev Immunol","Nature reviews. Immunology","Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Genetic Vectors; Humans; Immunity, Herd; Immunity, Innate; Immunization Schedule; Immunogenicity, Vaccine; Pandemics; Patient Safety; Pneumonia, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; Vaccines, Attenuated; Vaccines, DNA; Vaccines, Subunit; Vaccines, Virus-Like Particle; Viral Vaccines","Jeyanathan","Mangalakumari","McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada",NA
"176","32886952","10.1002/eji.202048723","Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.","The COVID-19 pandemic caused by the zoonotic coronavirus, SARS-CoV-2 has swept the world in 5 months. A proportion of cases develop severe respiratory tract infections progressing to acute respiratory distress syndrome and a diverse set of complications involving different organ systems. Faced with a lack of coronavirus-specific antiviral drugs and vaccines, hundreds of clinical trials have been undertaken to evaluate repurposed drugs. Convalescent plasma from recovered patients is an attractive","2020","10","13","Eur J Immunol","European journal of immunology","COVID-19; Convalescent plasma; Influenza; Passive immunization; SARS-CoV-2; Betacoronavirus; Biomarkers; COVID-19; Coronavirus Infections; Disease Progression; Humans; Immunization, Passive; Influenza A virus; Influenza, Human; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Severity of Illness Index; Treatment Outcome","Subbarao","Kanta","WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia",NA
"177","32884108","10.1038/d41573-020-00149-2","COVID-19 must catalyse changes to clinical development.",NA,"2020","10","22","Nat Rev Drug Discov","Nature reviews. Drug discovery","COVID-19; Clinical Trials as Topic; Coronavirus Infections; Health Equity; Humans; Information Dissemination; Pandemics; Patient Selection; Pneumonia, Viral; Viral Vaccines","MacKenzie","Rod",NA,NA
"178","32881641","10.1080/21645515.2020.1793712","Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19.","The emergence of the COVID-19 pandemic has resulted in a very large number of infections and high number of mortality. There is no specific therapeutic options that are approved for clinical use. Administration of convalescent plasma as a possible therapy was used in the case of viral pneumonia including SARS and influenza. There have been multiple studies of COVID-19 patients utilizing convalescent plasma. These studies employed different dosage levels and different regiments, were observationa","2021","01","15","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","COVID-19; Convalescent plasma; MERS-CoV; SARS; SARS-CoV-2; Antibodies, Viral; COVID-19; Coronavirus Infections; Humans; Immunization, Passive; Randomized Controlled Trials as Topic","Al-Tawfiq","Jaffar A","Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare , Dhahran, Saudi Arabia",NA
"179","32878912","10.4049/jimmunol.2000717","Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.","Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 and has since become a global pandemic. Pathogen-specific Abs are typically a major predictor of protective immunity, yet human B cell and Ab responses during COVID-19 are not fully understood. In this study, we analyzed Ab-secreting cell and Ab responses in 20 hospitalized COVID-19 patients. The patients exhibited typical symptoms of COVID-19 and presented with reduc","2020","10","27","J Immunol","Journal of immunology (Baltimore, Md. : 1950)","Adult; Aged; Antibodies, Neutralizing; Antibodies, Viral; B-Lymphocytes; Betacoronavirus; Biomarkers; C-Reactive Protein; COVID-19; Cohort Studies; Coronavirus Infections; Coronavirus Nucleocapsid Proteins; Female; Hospitalization; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Interleukin-6; Lymphocyte Activation; Male; Middle Aged; Nucleocapsid Proteins; Pandemics; Phosphoproteins; Pneumonia, Viral; SARS-CoV-2; Sweden","Varnait..","Renata","Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, 141 52 Stockholm, Sweden",NA
"180","32877576","10.1056/NEJMoa2026920","Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.","NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant. We initiated a randomized, placebo-controlled, phase 1-2 trial to evaluate the safety and immunogenicity of the rSARS-CoV-2 vaccine (in 5-..g and 25-..g doses, with or without Matrix-M1 adjuvant, and with observers unaware of trial-group assignments) in 131 healthy adults. In phase 1, vaccination co","2020","12","17","N Engl J Med","The New England journal of medicine","Adjuvants, Immunologic; Adolescent; Adult; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunization Schedule; Immunogenicity, Vaccine; Immunoglobulin G; Male; Middle Aged; Nanoparticles; Pandemics; Saponins; Spike Glycoprotein, Coronavirus; Th1 Cells; Vaccines, Synthetic; Young Adult","Keech","Cheryl","From Novavax, Gaithersburg, MD (C.K., G.A., I.C., A.R., P.R., S.N., J.S.P., M.Z., S.C.-C., H.Z., G.S., N.P., C.D., K.C., M.L., P.P.-A., N.F., V.S., L.F., B.W., G.M.G.), and the University of Maryland School of Medicine, Baltimore (M.B.F., R.E.H., J.L., M.M.G., S.W.)",NA
"181","32877397","","[Vaccines: from the identification of the microorganism to marketing. How long does it take?]","The development of a vaccine, particularly one that can help against the recent pandemic, is a topic that has recently attracted public opinion. More than ninety vaccines are currently being developed against Sars-Cov2 by universities and companies around the world. They are protein-based vaccines, viral vector vaccines, DNA or RNA vaccines and inactivated or attenuated viral vaccines. The development of a vaccine starts from the identification and characterization of the microorganism that caus","2020","09","07","Ig Sanita Pubbl","Igiene e sanita pubblica","Drug Approval; Humans; Product Surveillance, Postmarketing; Vaccination; Vaccines; Vaccines, Attenuated","Terracciano","Elisa","Scuola di Specializzazione in Igiene e Medicina Preventiva, Tor Vergata Universit.. degli Studi di Roma, Italia",NA
"182","32876223","10.17843/rpmesp.2020.372.5490",NA,"Disease caused by the new coronavirus (COVID-19) is characterized by fever, cough, and affection of the lower respiratory tract. It is associated with age, comorbidities and a weakened immune system. Typically, lymphopenias have been evidenced in severe cases and an excessive production of inflammatory cytokines (cytokine storm), which would explain the role of the hyperinflammatory response in the pathogenesis of COVID-19. Secondary inflammatory responses from virus reinfections may induce anti","2020","09","07","Rev Peru Med Exp Salud Publica","Revista peruana de medicina experimental y salud publica","Antiviral Agents; COVID-19; Coronavirus Infections; Cytokines; Humans; Pandemics; Pneumonia, Viral; Risk Factors; Social Isolation; Viral Vaccines","Lozada-Requena","Iv..n","Facultad de Ciencias y Filosof..a, Universidad Peruana Cayetano Heredia, Lima, Per",NA
"183","32875286","10.1016/j.jvacx.2020.100076","What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?","The first SARS-CoV-2 vaccine(s) will likely be licensed based on neutralizing antibodies in Phase 2 trials, but there are significant concerns about using antibody response in coronavirus infections as a sole metric of protective immunity. Antibody response is often a poor marker of prior coronavirus infection, particularly in mild infections, and is shorter-lived than virus-reactive T-cells; strong antibody response correlates with more severe clinical disease while T-cell response is correlate","2021","03","10","Vaccine X","Vaccine: X","Antibodies; Antibody-dependent enhancement; CD8 T-cells; COVID-19; Durable immunity; Protective immunity; SARS; SARS-CoV-2; T cell lifespan; T-cell epitopes; T-cells; Vaccines; Yellow Fever Vaccine","Hellerstein","Marc","University of California at Berkeley, United States",NA
"184","32874970","10.12998/wjcc.v8.i15.3156","Medical research during the COVID-19 pandemic.","The current pandemic of coronavirus disease 2019 (COVID-19) which was first detected in Wuhan, China in December 2019 is caused by the novel coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The virus has quickly spread to a large number of countries leading to a great number of deaths. Unfortunately, till today there is no specific treatment or vaccination for SARS-CoV-2. Most of the suggested treatment medications are based on in vitro laboratory investigat","2020","09","28","World J Clin Cases","World journal of clinical cases","COVID-19; Clinical trials; Pandemic; Research; SARS-CoV-2","AlNaamani","Khalid","Division of Gastroenterology, Department of Internal Medicine, Armed Forces Hospital, Muscat 999046, Oman",NA
"185","32867979","10.1016/j.psj.2020.05.054","Alteration of immunological parameters in infectious bronchitis vaccinated-specific pathogen-free broilers after the use of different infectious bursal disease vaccines.","The vaccines currently available to control infectious bursal disease (IBD) include live-attenuated and inactivated vaccines, immune-complex vaccines, and vaccines consisting of viral constructs of herpesvirus of turkeys genetically engineered to express VP2 surface protein. To evaluate the impact of vaccines on the chicken immune system, 2 animal trials were performed in specific pathogen-free broiler chickens. In trial 1, birds were either vaccinated when they are one-day old with a dual recom","2020","09","10","Poult Sci","Poultry science","avian coronavirus; immune-complex vaccine; infectious bursal disease virus; vectored vaccine; Animals; Birnaviridae Infections; Bursa of Fabricius; Chickens; Coronavirus Infections; Infectious bronchitis virus; Infectious bursal disease virus; Newcastle disease virus; Poultry Diseases; Specific Pathogen-Free Organisms; Vaccination; Vaccines, Attenuated; Viral Vaccines","Lupini","Caterina","Department of Veterinary Medical Sciences, University of Bologna, 40064 Ozzano dell'Emilia, BO, Italy",NA
"186","32864509","10.1016/j.jacbts.2020.06.010","Update to Drugs, Devices, and the FDA: How Recent Legislative Changes Have Impacted Approval of New Therapies.","Two major legislative actions since 2015, the 21st Century Cures Act of 2016 and the U.S. Food and Drug Administration (FDA) Reauthorization Act of 2017, contain significant provisions that potentially streamline drug development times, and by extension, may reduce costs. Evidence suggests, however, that development times have already been significantly affected by previous legislation and FDA programs, through accelerated approval pathways and adoption of more flexible definitions of clinical e","2020","11","18","JACC Basic Transl Sci","JACC. Basic to translational science","AA, Accelerated Approval; BT, Breakthrough Therapy; COVID-19; DAB, drugs and biologics; EUA, Emergency Use Application; FDA, U.S. Food and Drug Administration; FDARA, Food and Drug Administration Reauthorization Act; IND, Investigational New Drug; NDA, New Drug Application; PDUFA, Prescription Drug User Fee Act; RMAT, Regenerative Medicine Advanced Therapy; drug approval; drug legislation; emergency use; expanded access; pandemic; vaccine approval","Van Norman","Gail A","Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington",NA
"187","32862824","10.2174/156802662018200703154334","COVID-19: Small-Molecule Clinical Trials Landscape.",NA,"2020","09","10","Curr Top Med Chem","Current topics in medicinal chemistry","Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Coronavirus Infections; Drug Repositioning; Europe; Humans; Pandemics; Pneumonia, Viral; Registries; SARS-CoV-2; Small Molecule Libraries; United States; Viral Vaccines","Ferreira","Leonardo L G","Laboratory of Medicinal and Computational Chemistry, Center for Research and Innovation in Biodiversity and Drug Discovery, Physics Institute of Sao Carlos, University of Sao Paulo, Av. Joao Dagnone 1100, Sao Carlos - SP, 13563-120, Brazil",NA
"188","32862110","10.1016/j.intimp.2020.106928","Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.","Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against COVID-19. Nevertheless, currently, no proven effective therapies for this virus exists. The vaccines are deemed as a significant part of disease prevention for emerging viral diseases, since, in sever","2020","11","23","Int Immunopharmacol","International immunopharmacology","COVID-19; Immunopathogenesis; SARS-CoV-2; Vaccines; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Humans; Immunogenicity, Vaccine; Lung; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Viral Vaccines","Mirzaei","Rasoul","Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran","rasul.micro92@gmail.com"
"189","32861315","10.1016/S0140-6736(20)31821-3","COVID-19 vaccine trials should seek worthwhile efficacy.",NA,"2020","09","21","Lancet","Lancet (London, England)","COVID-19; COVID-19 Vaccines; Controlled Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Viral Vaccines; World Health Organization","Krause","Philip","Center for Biologics Evaluation and Research, US Food and Drug Administration, Washington, DC, USA",NA
"190","32857836","10.1093/cid/ciaa1290","Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers.","WHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. The AG included experts in design, establishment and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2's potential to cause severe/fatal illness, its high transmissibility, and lack of a &quot;rescue tr","2021","01","10","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","COVID-19; SARS-CoV-2; adult volunteers; challenge model; experimental challenge","Levine","Myron M","Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA",NA
"191","32857671","10.1089/omi.2020.0122","Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.","Coronavirus disease-2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is evolving across the world and new treatments are urgently needed as with vaccines to prevent the illness and stem the contagion. The virus affects not only the lungs but also other tissues, thus lending support to the idea that COVID-19 is a systemic disease. The current vaccine and treatment development strategies ought to consider such systems medicine perspectives rather ","2021","01","12","OMICS","Omics : a journal of integrative biology","COVID-19; JAK; SARS-CoV-2; STAT; cytokines; drug repurposing; interleukin-6; natural products; Antiviral Agents; Biological Products; COVID-19; Clinical Trials as Topic; Cytokine Release Syndrome; Cytokines; Drug Repositioning; Herbal Medicine; Humans; Interleukin-6; SARS-CoV-2; Signal Transduction","Dzobo","Kevin","International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa",NA
"192","32854391","10.3390/vaccines8030474","Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2.","Coronavirus disease 2019 (COVID-19) is the biggest health challenge of the 21st century, affecting millions of people globally. The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has ignited an unprecedented effort from the scientific community in the development of new vaccines on different platforms due to the absence of a broad and effective treatment for COVID-19 or prevention strategy for SARS-CoV-2 dissemination. Based on 50 current studies selected from the main ","2020","10","27","Vaccines (Basel)","Vaccines","COVID-19; D); SARS-CoV-2; immunization; research and development (R&amp;amp; vaccine","Rego","Gabriel N A","Hospital Israelita Albert Einstein, S..o Paulo 05652-900, Brazil",NA
"193","32851596","10.1007/s40199-020-00371-8","COVID-19 vaccines: ethical framework concerning human challenge studies.","The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develop a new COVID-19 vaccine is pressing; however, it is likely to take a long time, possibly several years. This is due to the time required to demonstrate the safety and efficacy of the proposed vaccine. and the ti","2020","12","07","Daru","Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","COVID-19 vaccines; Human challenge studies; Randomized clinical trials; Risk taking; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Human Experimentation; Humans; SARS-CoV-2; Time Factors","Calina","Daniela","Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania. calinadaniela@gmail","calinadaniela@gmail.com"
"194","32850977","10.3389/fmolb.2020.00196","Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19.","The coronavirus disease 2019 (COVID-19), is a highly contagious transmittable disease caused by a recently discovered coronavirus, pathogenic SARS-CoV-2. Followed by the emergence of highly pathogenic coronaviruses in 2003 SARS-CoV, in 2012 MERS-CoV, now in 2019 pathogenic SARS-CoV-2, is associated with a global &quot;pandemic&quot; situation. In humans, the effects of these viruses are correlated with viral pneumonia, severe respiratory tract infections. It is believed that interaction between ","2020","09","28","Front Mol Biosci","Frontiers in molecular biosciences","COVID-19; Mannose-binding lectin; SARS-CoV-2; TMPRSS2; cytokine storm; immunomodulators; innate immunity","Chatterjee","Swapan K","Molecular Pharma Pvt., Ltd., Kolkata, India",NA
"195","32850922","10.3389/fmed.2020.00480","Treatment Options for COVID-19: A Review.","Background: The recent COVID-19 pandemic sweeping the globe has caused great concern worldwide. Due to the limited evidence available on the dynamics of the virus and effective treatment options available, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a huge impact in terms of morbidity and mortality. The economic impact is still to be assessed. Aims: The purpose of this article is to review the evidence for the multiple treatment options available, to consid","2020","09","28","Front Med (Lausanne)","Frontiers in medicine","COVID-19; SARS-CoV-2; chloroquine/hydroxychloroquine; immunoglobulin; ivermectin; remdesivir; tocilizumab","Ali","Mukarram Jamat","Department of Medicine, King Edward Medical University, Lahore, Pakistan",NA
"196","32850116","10.12688/f1000research.25998.1","Development of vaccines for SARS-CoV-2.","COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies bei","2020","09","01","F1000Res","F1000Research","COVID-19; SARS-CoV-2; Vaccines; Betacoronavirus; COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Viral Vaccines","Ng","Wern Hann","Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia",NA
"197","32849449","10.3389/fmicb.2020.01858","CoronaVR: A Computational Resource and Analysis of Epitopes and Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2.","In December 2019, the Chinese city of Wuhan was the center of origin of a pneumonia-like disease outbreak with an unknown causative pathogen. The CDC, China, managed to track the source of infection to a novel coronavirus (2019-nCoV; SARS-CoV-2) that shares approximately 79.6% of its genome with SARS-CoV. The World Health Organization (WHO) initially declared COVID-19 as a Public Health Emergency of International Concern (PHEIC) and later characterized it as a global pandemic on March 11, 2020. ","2020","09","28","Front Microbiol","Frontiers in microbiology","2019-nCoV; COVID-19; SARS-CoV-2; epitopes; primers; therapeutics","Gupta","Amit Kumar","Virology Unit and Bioinformatics Centre, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Sector 39-A, Chandigarh, India",NA
"198","32846196","10.1016/j.virusres.2020.198141","Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.","The recent outbreak of the betacoronavirus SARS-CoV-2 has become a significant concern to public health care worldwide. As of August 19, 2020, more than 22,140,472 people are infected, and over 781,135 people have died due to this deadly virus. In the USA alone, over 5,482,602 people are currently infected, and more than 171,823 people have died. SARS-CoV-2 has shown a higher infectivity rate and a more extended incubation period as compared to previous coronaviruses. SARS-CoV-2 binds much more ","2020","10","07","Virus Res","Virus research","COVID-19; SARS-CoV-2; Spike protein; Therapeutic; Vaccine; Angiotensin-Converting Enzyme 2; Antibodies, Viral; Antibody-Dependent Enhancement; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Genetic Vectors; Humans; Immunogenicity, Vaccine; Pandemics; Patient Safety; Peptidyl-Dipeptidase A; Pneumonia, Viral; Receptors, Virus; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, Attenuated; Vaccines, DNA; Vaccines, Subunit; Vaccines, Virus-Like Particle; Viral Vaccines","Samrat","Subodh Kumar","Wadsworth Center, New York State Department of Health, 120 New Scotland Ave, Albany, NY 12208, USA",NA
"199","32846056","10.1056/NEJMp2027405","Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach.",NA,"2020","11","10","N Engl J Med","The New England journal of medicine","Advisory Committees; Betacoronavirus; COVID-19; COVID-19 Vaccines; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; Coronavirus Infections; Drug Approval; Drug Development; Drug Industry; Humans; Immunization; Pandemics; Pneumonia, Viral; RNA, Viral; SARS-CoV-2; Time Factors; United States; United States Food and Drug Administration; Viral Vaccines","Slaoui","Moncef","From Operation Warp Speed, Department of Health and Human Services, Washington, DC",NA
"200","32845317","10.1093/infdis/jiaa456","Large Simple Double-Blind Randomized Trials for the Rapid Assessment of the Effectiveness of COVID-19 Vaccines.",NA,"2020","10","06","J Infect Dis","The Journal of infectious diseases","Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Double-Blind Method; Humans; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Viral Vaccines","Hasford","Joerg","Institute for Medical Information Processing, Biometry, and Epidemiology, University of Munich, Munich, Germany",NA
"201","32845250","","COVID-19: Prospective Challenges and Potential Vaccines.","RNA viruses exhibit an extraordinary ability to evolve in a changing environment and to switch from animal hosts to humans. The ongoing COVID-19 pandemic, recognized as a respiratory disease, is an example of zoonotic transmission of the RNA virus known as SARS-CoV-2. The development and regulatory approval of a vaccine against SARS-CoV-2 pose multiple preventive and therapeutic challenges, especially during an ongoing pandemic. The review intended to examine the challenges and recent achievemen","2020","09","15","Altern Ther Health Med","Alternative therapies in health and medicine","Animals; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Prospective Studies; SARS-CoV-2; Viral Vaccines","Shahid Nadeem","Muhammad",NA,NA
"202","32844107","10.1016/j.jemep.2020.100580","COVID-19 response in Nigeria: Health system preparedness and lessons for future epidemics in Africa.","The coronavirus disease 2019 (COVID-19) will continue to have a significant impact on the way we live for at least the next few years until the scale-up of production and administration of an effective vaccine. Unfortunately, this will not be the last pandemic of infectious diseases the world will experience, and the next one may have more devastating consequences in Africa than COVID-19, unless critical lessons for the future are learnt now for more rapid and robust containment measures. Severe","2021","01","26","Ethics Med Public Health","Ethics, medicine, and public health","Africa; Coronavirus disease 2019 (COVID-19); Health system preparedness; Nigeria; SARS-CoV-2","Etteh","C C","Department of medical biochemistry, Imo State university, Owerri, Imo State, Nigeria",NA
"203","32841042","10.1177/0963689720940719","The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy.","Coronavirus disease 2019 or COVID-19 is highly infectious, which can lead to acute and chronic debilitating symptoms, as well as mortality. The advent of safe and effective vaccines or antiviral drugs remains distant in the future. Practical public health measures, such as social distancing, hand washing, and wearing a face mask, are the current recommended guidelines by the Centers for Disease Control and Prevention for limiting the spread of the virus. Weakened immune system and aberrant infla","2020","09","09","Cell Transplant","Cell transplantation","convalescent plasma; immunoglobulin; mesenchymal stem cells; vaccine; virus; Antibodies, Neutralizing; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunization, Passive; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pandemics; Pneumonia, Viral; Public Health Practice; SARS-CoV-2; Viral Load","Borlongan","Mia C","38University of California Berkeley, Berkeley, CA, USA",NA
"204","32840177","10.4155/tde-2020-0085","An industry update: the latest developments in therapeutic delivery covering May 2020.","The present industry update covers the period 1-31 May 2020, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature.","2020","10","08","Ther Deliv","Therapeutic delivery","COVID-19 vaccines; antibody...drug conjugates; controlled-release; nanoparticles; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Device Approval; Drug Delivery Systems; Drug Industry; Humans; Nanostructures; Viral Vaccines","Steinbach","Oliver C","Imagion Biosystems, Inc., 10355 Science Center Drive, San Diego, CA 92121, USA",NA
"205","32839960","10.1111/anae.15253","Airway management guidance for the endemic phase of COVID-19.","It is now apparent that severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) will remain endemic for some time. Improved therapeutics and a vaccine may shorten this period, but both are far from certain. Plans must be put in place on the assumption that the virus and its disease will continue to affect the care of patients and the safety of staff. This will impact particularly on airway management due to the inherent risk to staff during such proce","2021","01","14","Anaesthesia","Anaesthesia","COVID-19; airway; anaesthesia; coronavirus; intubation; Airway Management; Anesthesia; COVID-19; Humans; Infection Control; Operating Rooms; Pandemics; Personal Protective Equipment","Cook","T M","Department of Anaesthesia and Intensive Care Medicine, Royal United Hospital NHS Trust, Bath, UK",NA
"206","32839784","10.1101/2020.08.17.20176651","RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (COVID-19), have spread to millions of people globally. Multiple vaccine candidates are under development, but no vaccine is currently available. Healthy adults 18-55 and 65-85 years of age were randomized in an ongoing, placebo-controlled, observer-blinded dose-escalation study to receive 2 doses at 21-day intervals of placebo or either of 2 lipid nanoparticle-formulated, ","2020","12","16","medRxiv","medRxiv : the preprint server for health sciences",NA,"Walsh","Edward E",NA,NA
"207","32839593","10.1038/d41586-020-02450-x","The unequal scramble for coronavirus vaccines - by the numbers.",NA,"2020","09","03","Nature","Nature","Business; Public health; SARS-CoV-2; Vaccines; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Confidentiality; Coronavirus Infections; Developed Countries; Drug Approval; Drug Costs; Drug Industry; Global Health; Healthcare Disparities; Hoarding; Humans; Influenza A Virus, H1N1 Subtype; International Cooperation; Needs Assessment; Time Factors; Viral Vaccines","Callaway","Ewen",NA,NA
"208","32839191","10.1136/bmj.m3270","Russian SARS-CoV-2 vaccine.",NA,"2020","09","07","BMJ","BMJ (Clinical research ed.)","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Evidence-Based Medicine; Global Health; Government Regulation; Humans; Pandemics; Patient Safety; Pneumonia, Viral; Risk; Russia; SARS-CoV-2; Viral Vaccines","Caddy","Sarah","Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge, UK",NA
"209","32839164","10.1136/bmj.m3260","Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?",NA,"2020","09","07","BMJ","BMJ (Clinical research ed.)","Access to Information; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Evidence-Based Medicine; Global Health; Humans; Pandemics; Pneumonia, Viral; Practice Patterns, Physicians'; SARS-CoV-2; Viral Vaccines","Johnson","Raymond M","Yale School of Medicine, New Haven, Connecticut, USA Raymond.Johnson@yale.edu pdoshi@rx.umaryland","Raymond.Johnson@yale.edu"
"210","32838299","10.1002/aisy.202000070","Addressing COVID-19 Drug Development with Artificial Intelligence.","The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that led to the COVID-19 (Coronavirus Disease 2019) pandemic, has resulted in substantial overburdening of healthcare systems as well as an economic crisis on a global scale. This has in turn resulted in widespread efforts to identify suitable therapies to address this aggressive pathogen. Therapeutic antibody and vaccine development are being actively explored, and a phase I clinical trial of mRNA-1273 whic","2020","09","28","Adv Intell Syst","Advanced intelligent systems (Weinheim an der Bergstrasse, Germany)","COVID-19; artificial intelligence; combination therapy; drug development; severe acute respiratory syndrome coronavirus 2","Ho","Dean","The N. 1 Institute for Health (N. 1) National University of Singapore Singapore 117456 Singapore",NA
"211","32838283","10.1016/j.bsheal.2020.07.001","Debate on Bacille Calmette-Gu..rin vaccination against COVID-19: Is it worth performing clinical trials?","The non-specific beneficial effects of Bacille Calmette-Gu..rin (BCG) vaccination suggest that this vaccine might play a role in protecting individuals against severe coronavirus disease 2019 (COVID-19). Several studies propose that BCG vaccination may increase the body's immunity, thereby preventing respiratory infections caused by other respiratory pathogens. As the number of deaths due to COVID-19 is increasing rapidly and there is no specific treatment available to date, scientists are evalu","2020","09","30","Biosaf Health","Biosafety and health","Bacille Calmette-Gu..rin; COVID-19; Clinical trial; Non-specific effect; RCT","Aziz","Asma Binte","University of Oslo, Faculty of Medicine, Oslo, Norway",NA
"212","32838206","10.1016/j.mayocpiqo.2020.07.004","A Narrative Review of Emerging Therapeutics for COVID-19.","The novel severe acute respiratory syndrome coronavirus 2, the causal agent of coronavirus disease 2019 (COVID-19), quickly spread around the world, resulting in the most aggressive pandemic experienced in more than 100 years. Research on targeted therapies and vaccines has been initiated on an unprecedented scale and speed but will take months and even years to come to fruition. Meanwhile, the efficacy of emerging therapeutics for use in treating COVID-19 is feverishly being investigated to ide","2020","12","11","Mayo Clin Proc Innov Qual Outcomes","Mayo Clinic proceedings. Innovations, quality &amp; outcomes","COVID-19, coronavirus disease 2019; CPT, convalescent plasma therapy; CQ, chloroquine; EC50, half-maximal effective concentration; HCQ, hydroxychloroquine; ICU, intensive care unit; IL-6, interleukin 6; JAK, Janus kinase; LPV/RTV, lopinavir/ritonavir; MERS, Middle East respiratory syndrome; RCT, randomized controlled trial; SARS, severe acute respiratory syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization","Willis","Van C","IBM Watson Health, Center for AI, Research, and Evaluation, Cambridge, MA",NA
"213","32837854","10.1007/s40495-020-00226-5","Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update.","The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for causing coronavirus disease 2019 (COVID-19), marked the third time in the twenty-first century when a new, highly pathogenic human coronavirus outbreak has led to an epidemic. The COVID-19 epidemic has emerged in late December 2019 in Wuhan city of China and spread rapidly to other parts of the world. This quick spread of SARS-CoV-2 infection to many states across the globe affecting many people ha","2020","09","28","Curr Pharmacol Rep","Current pharmacology reports","A recent update; COVID-19; Pharmacological therapy; Pipeline drugs; SARS-CoV-2","Kumari","Puja","Department of Pharmacology, Post Graduate Institute of Medical Education &amp",NA
"214","32837550","10.1007/s41649-020-00125-3","The Perfect Moral Storm: Diverse Ethical Considerations in the COVID-19 Pandemic.","The COVID-19 pandemic has both exposed and created deep rifts in society. It has thrust us into deep ethical thinking to help justify the difficult decisions many will be called upon to make and to protect from decisions that lack ethical underpinnings. This paper aims to highlight ethical issues in six different areas of life highlighting the enormity of the task we are faced with globally. In the context of COVID-19, we consider health inequity, dilemmas in triage and allocation of scarce reso","2020","09","28","Asian Bioeth Rev","Asian bioethics review","COVID-19; Health inequity; Immunity passports; Resource allocation; SARS-CoV-2; Tracing apps; Triage; Vaccines","Xafis","Vicki","SHAPES Initiative, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore",NA
"215","32837100","10.1016/j.jaim.2020.07.002","An Ayurvedic Perspective along with in Silico Study of the Drugs for the Management of Sars-Cov-2.","Covid-19 is the disease caused by SARS-CoV2, it was identified in Wuhan, China, in 2019. It then extended across the globe and was termed as a pandemic in 2020. Though research work on its vaccine and drugs are carried out across the globe, it is even necessary to look over it through alternative sciences. The objective of this study is to look over the disease through Ayurvedic perspective, analyse possible pathologies, select appropriate drugs and to study in-silico screening on these selected","2020","09","28","J Ayurveda Integr Med","Journal of Ayurveda and integrative medicine","Ayurveda; Covid 19; Molecular Docking; Pandemic","Gandhi","Abhay Jayprakash","IPGT &amp",NA
"216","32837093","10.1016/j.jceh.2020.06.003","COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!","The coronavirus disease 2019 (COVID-19) has turned into a global human tragedy and economic devastation. Governments have implemented lockdown measures, blocked international travel, and enforced other public containment measures to mitigate the virus morbidity and mortality. As of today, no drug has the power to fight the infection and bring normalcy to the utter chaos. This leaves us with only one choice namely an effective and safe vaccine that shall be manufactured as soon as possible and av","2021","01","10","J Clin Exp Hepatol","Journal of clinical and experimental hepatology","ADE, Antibody-Dependent Enhancement; CEPI, Coalition for Epidemic Preparedness Innovations; COVID-19; COVID-19, Coronavirus Disease 2019; MERS-CoV, Middle East Respiratory Syndrome Coronavirus; MHC, Major Histocompatibility Complex; SARS-CoV-2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; WHO, World Health Organization; coronavirus; platform technology clinical trials; vaccine","Khuroo","Mohammad S","Medicine, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, India",NA
"217","32837030","10.1007/s12291-020-00907-4","Novel Stem Cells and Nucleic Acid-Based Vaccine Trials Against Viral Outbreak: A Systematic Evaluation During COVID-2019 Pandemic.","The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak, the cause of coronavirus disease (COVID-19), has influenced health globally. So far, there are no established management options and prophylaxis for those who have been exposed to SARS-CoV-2, and those who develop COVID-19. Documented scientific evidences in similar viral outbreaks in past suggested few therapy regimens. These rather have not shown promising results in management of current pandemic. So, in the cu","2020","09","28","Indian J Clin Biochem","Indian journal of clinical biochemistry : IJCB","COVID-19; DNA vaccine; Nucleic acid based vaccines; RNA vaccine; Stem cell based vaccine; Viral disease","Maurya","Chandan Kumar","Department of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, 273008 India",NA
"218","32834921","10.1186/s13362-020-00091-3","Beyond just &quot;flattening the curve&quot;: Optimal control of epidemics with purely non-pharmaceutical interventions.","When effective medical treatment and vaccination are not available, non-pharmaceutical interventions such as social distancing, home quarantine and far-reaching shutdown of public life are the only available strategies to prevent the spread of epidemics. Based on an extended SEIR (susceptible-exposed-infectious-recovered) model and continuous-time optimal control theory, we compute the optimal non-pharmaceutical intervention strategy for the case that a vaccine is never found and complete contai","2020","09","28","J Math Ind","Journal of mathematics in industry","COVID-19; Dynamical systems; Mathematical epidemiology; Non-pharmaceutical interventions; Optimal control; Reproduction number; SARS-CoV2","Kantner","Markus","Weierstrass Institute for Applied Analysis and Stochastics (WIAS), Mohrenstr. 39, Berlin, 10117 Germany",NA
"219","32834680","10.1016/j.tranpol.2020.07.001","Insights into the impact of COVID-19 on household travel and activities in Australia - The early days under restrictions.","When 2020 began, we had no idea what was to unfold globally as we learnt about the Novel-Coronavirus in Wuhan, in the Hubei province of China. As this virus spread rapidly, it became a matter of time before many countries began to implement measures to try and contain the spread of the disease. COVID-19 as it is referred to, resulted in two main approaches to fighting the viral pandemic, either through a progressive set of measures to slow down the number of identified cases designed to 'flatten","2020","09","28","Transp Policy (Oxf)","Transport policy","Air travel; Attitudes; Australia; COVID-19; Coronavirus; Shopping; Survey; Travel activity; Working; Working from home","Beck","Matthew J","Institute of Transport and Logistics Studies (ITLS), The University of Sydney Business School, Sydney, NSW, 2006, Australia",NA
"220","32834603","10.1016/j.chaos.2020.110049","Modeling and forecasting the COVID-19 pandemic in India.","In India, 100,340 confirmed cases and 3155 confirmed deaths due to COVID-19 were reported as of May 18, 2020. Due to absence of specific vaccine or therapy, non-pharmacological interventions including social distancing, contact tracing are essential to end the worldwide COVID-19. We propose a mathematical model that predicts the dynamics of COVID-19 in 17 provinces of India and the overall India. A complete scenario is given to demonstrate the estimated pandemic life cycle along with the real da","2020","11","05","Chaos Solitons Fractals","Chaos, solitons, and fractals","Basic reproduction number; COVID-19; Isolation; Mathematical model; Model prediction; Sensitivity analysis","Sarkar","Kankan","Department of Mathematics, Malda College, Malda, West Bengal 732101, India",NA
"221","32832438","10.4103/idoj.IDOJ_328_20","Safer Practice of Aesthetic Dermatology during the COVID-19 Pandemic: Recommendations by SIG Aesthetics (IADVL Academy).","The COVID-19 pandemic caused by the SARS-CoV-2 virus, has changed the homeostasis of the medical world. In this critical phase, in addition to the general recommendations issued by World Health Organization (WHO) for medical practitioners and health care givers, certain other precautions and safe care practices need to be emphasized which are unique to each branch of medicine. Aesthetic dermatology is no exception. With aesthetic treatments on the rise, it is pertinent to formulate safe practice","2020","09","28","Indian Dermatol Online J","Indian dermatology online journal","Aesthetic dermatology; COVID-19; recommendations; teledermatology","Arora","Gulhima","Consultant Dermatologist, ehektagul Dermaclinic, New Delhi, India",NA
"222","32829400","10.1093/cid/ciaa1223","BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden.","The Bacille Calmette-Gu..rin (BCG) tuberculosis vaccine has immunity benefits against respiratory infections. Accordingly, it has been hypothesized to have a protective effect against COVID-19. Recent research found that countries with universal BCG childhood vaccination policies tend to be less affected by the COVID-19 pandemic. However, such ecological studies are biased by numerous confounders. Instead, this paper takes advantage of a rare nationwide natural experiment that took place in Swed","2020","09","22","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","BCG; Covid-19; Regression discontinuity","de Chaisemartin","Cl..ment","Department of Economics, University of California, Santa Barbara, Santa Barbara, CA 93106, USA",NA
"223","32821086","10.2147/DDDT.S261154","A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.","The novel coronavirus 2019 (2019-nCoV), formally named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel human infectious coronavirus. The disease caused by SARS-CoV-2 is named COVID-19. Development and manufacturing of specific therapeutics and vaccines to treat COVID-19 are time-consuming processes. At this time, using available conventional therapeutics along with other treatment options may be useful to fight COVID-19. In different clinical trials, efficacy of remdesiv","2020","08","27","Drug Des Devel Ther","Drug design, development and therapy","COVID-19; RNA-dependent RNA polymerase; SARS-CoV-2; remdesivir; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Virus Replication","Hashemian","Seyed MohammadReza","Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran",NA
"224","32820746","10.15585/mmwr.rr6908a1","Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season.","This report updates the 2019-20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ...6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live atten","2020","08","25","MMWR Recomm Rep","MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports","Adolescent; Adult; Advisory Committees; Aged; Centers for Disease Control and Prevention, U.S.; Child; Child, Preschool; Female; Humans; Immunization Schedule; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Pregnancy; Randomized Controlled Trials as Topic; Risk Assessment; Seasons; United States; Vaccines, Attenuated; Young Adult","Grohskopf","Lisa A",NA,NA
"225","32817961","10.1101/2020.08.13.20157222","Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera.","The on-going coronavirus disease 2019 (COVID-19) pandemic has mobilized a global effort to develop vaccines and therapeutics that inhibit viral entry by inducing or transferring antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (CoV2-S). Phase I/II vaccine clinical trials, monoclonal antibodies, and convalescent sera have all shown promise. However, these efforts often require extensive screening with the live virus under onerous high bioconta","2021","02","23","medRxiv","medRxiv : the preprint server for health sciences",NA,"Oguntuyo","Kasopefoluwa Y","Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029",NA
"226","32817958","10.1101/2020.08.07.20170456","Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates.","Significant progress has already been made in development and testing of SARS-CoV-2 vaccines, and Phase III clinical trials have begun for 6 novel vaccine candidates to date. These Phase III trials seek to demonstrate direct benefits of a vaccine on vaccine recipients. However, vaccination is also known to bring about indirect benefits to a population through the reduction of virus circulation. The indirect effects of SARS-CoV-2 vaccination can play a key role in reducing case counts and COVID-1","2021","01","14","medRxiv","medRxiv : the preprint server for health sciences",NA,"Gallagher","Molly E","Department of Biology, Emory University, Atlanta, GA, USA",NA
"227","32813843","10.1590/1516-3180.2020.0208.r1.15062020","Study of ongoing registered clinical trials on COVID-19: a narrative review.","The dangerous SARS-CoV-2 virus first emerged in China in December 2019 and has rapidly spread worldwide. Currently, it has affected more than 2,850,000 people. No vaccine or drug is available yet, and therefore researchers and scientists are striving to identify potential drugs or vaccines for combating this virus. We were unable to find any review of the literature or analysis on ongoing registered clinical trials that reported diagnostic tests, therapeutics, vaccines and devices for COVID-19 a","2020","11","25","Sao Paulo Med J","Sao Paulo medical journal = Revista paulista de medicina","Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States","Rabby","Md Insiat Islam","BSc, Engineer and Master's Student, Department of Mechanical and Manufacturing Engineering, Universiti Putra Malaysia, Seri Kembangan, Selangor, Malaysia",NA
"228","32808972","10.1001/jama.2020.15589","Ethical Considerations for COVID-19 Vaccine Trials in Correctional Facilities.",NA,"2020","09","29","JAMA","JAMA","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Prisoners; SARS-CoV-2; Therapeutic Human Experimentation; United States; Vaccination; Viral Vaccines","Wang","Emily A","SEICHE Center of Health and Justice, Yale School of Medicine, New Haven, Connecticut",NA
"229","32808095","10.1007/s10654-020-00675-8","Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy.","Researchers have been working quickly and collaboratively for the development of vaccines against the COVID-19 virus. The effort of the scientific community in searching a vaccine for COVID-19 may be hampered by a diffused vaccine hesitancy. Two waves of data collection on representative samples of the Italian population (during the &quot;first&quot; and &quot;second&quot; phase of the Italian Covid-19 mitigation strategy) were conducted to understand citizens' perceptions and behaviors about pr","2020","09","16","Eur J Epidemiol","European journal of epidemiology","Covid-19; Trust in science; Trust in vaccine; Vaccine effectiveness; Vaccine hesitancy; Betacoronavirus; Biomedical Research; COVID-19; COVID-19 Vaccines; Communication; Coronavirus Infections; Health Knowledge, Attitudes, Practice; Humans; Italy; Pandemics; Patient Acceptance of Health Care; Pneumonia, Viral; SARS-CoV-2; Trust; Vaccination; Viral Vaccines","Palamenghi","Lorenzo","Department of Psychology, EngageMinds HUB - Consumer, Food and Health Engagement Research Center, Universit.. Cattolica del Sacro Cuore, Milan, Italy",NA
"230","32802896","10.1155/2020/8624963","The Application of Single-Cell RNA Sequencing in Vaccinology.","Single-cell RNA sequencing allows highly detailed profiling of cellular immune responses from limited-volume samples, advancing prospects of a new era of systems immunology. The power of single-cell RNA sequencing offers various opportunities to decipher the immune response to infectious diseases and vaccines. Here, we describe the potential uses of single-cell RNA sequencing methods in prophylactic vaccine development, concentrating on infectious diseases including COVID-19. Using examples from","2020","08","24","J Immunol Res","Journal of immunology research","Animals; Betacoronavirus; COVID-19; Cell Line; Clinical Trials as Topic; Coronavirus Infections; Disease Models, Animal; Drug Evaluation, Preclinical; Host-Pathogen Interactions; Humans; Immunity, Cellular; Immunity, Innate; Immunogenicity, Vaccine; Pandemics; Pneumonia, Viral; RNA, Viral; RNA-Seq; SARS-CoV-2; Single-Cell Analysis; Vaccinology; Viral Vaccines","No..","Andr..s","The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK",NA
"231","32800805","10.1016/j.virusres.2020.198114","COVID-19 Vaccine: A comprehensive status report.","The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. Published investigations mostly on SARS-CoV and to some extent on MERS has taught lessons on vaccination strategies to this novel coronavirus. This is attributed to the fact that SARS-CoV-2 uses the same receptor as SARS-CoV on the host cell i.e. human Angiotensin Converting Enzyme 2 (hACE2) and is approximately 79% similar genetically to S","2020","10","07","Virus Res","Virus research","COVID-19; Clinical Trials; Convalescent Plasma Therapy; Monoclonal Antibodies; SARS-CoV-2; Vaccine; Angiotensin-Converting Enzyme 2; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Genetic Vectors; Humans; Immunity, Innate; Immunization, Passive; Immunogenicity, Vaccine; Pandemics; Patient Safety; Peptidyl-Dipeptidase A; Pneumonia, Viral; Receptors, Virus; SARS-CoV-2; Vaccines, Attenuated; Vaccines, DNA; Vaccines, Subunit; Vaccines, Virus-Like Particle; Viral Vaccines","Kaur","Simran Preet","Department of Microbiology, Ram Lal Anand College, University of Delhi, Benito Juarez Road, New Delhi 110021, India",NA
"232","32798320","10.1111/dewb.12283","Considerations for stakeholder engagement and COVID-19 related clinical trials' conduct in sub-Saharan Africa.","The aim of this study is to determine how stakeholder engagement can be adapted for the conduct of COVID-19-related clinical trials in sub-Saharan Africa. Nine essential stakeholder engagement practices were reviewed: formative research; stakeholder engagement plan; communications and issues management plan; protocol development; informed consent process; standard of prevention for vaccine research and standard of care for treatment research; policies on trial-related physical, psychological, fi","2021","03","04","Dev World Bioeth","Developing world bioethics","COVID-19; GPP-EP; SAR-COV-2; stakeholder engagement; sub-Saharan Africa","Folayan","Morenike Oluwatoyin",NA,NA
"233","32795830","10.1016/j.mehy.2020.110043","Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19.","The delayed lung damage after SARS-CoV-2 infection may be caused by an autoimmune response to ACE2 induced by forced presentation of the ACE2 protein in a complex with CoV Spike in Fc Receptor positive Antigen Presenting Cells in the lung. The likelihood that this hypothesis is valid is low, but it is easily tested. 1) Autoantibodies and T cells to ACE2 may be found in patients with the lung damage but not in those without 2) There may be an HLA linkage with the delayed lung disease 3) Vaccines ","2021","01","05","Med Hypotheses","Medical hypotheses","Angiotensin-Converting Enzyme 2; Antigen-Presenting Cells; Autoantibodies; Autoimmunity; Binding Sites; COVID-19; HLA Antigens; Humans; Inflammation; Lung Diseases; Models, Theoretical; Protein Binding; Protein Domains; Receptors, Fc; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Virus Internalization","Townsend","Alain","Human Immunology Unit, Weatherall Institute, Oxford OX39DS, United Kingdom. Electronic address: Alain.townsend@imm.ox.ac","Alain.townsend@imm.ox.ac.uk"
"234","32795413","10.1016/j.cell.2020.07.024","A Thermostable mRNA Vaccine against COVID-19.","There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (called ARCoV). Intramuscular immunization of ARCoV mRNA-LNP elicited robust neutra","2020","09","17","Cell","Cell","COVID-19; SARS-CoV-2; lipid nanoparticle; mRNA vaccine; mouse-adapted strain; non-human primate; protection; Animals; Antibodies, Neutralizing; Binding Sites; COVID-19 Vaccines; Chlorocebus aethiops; Coronavirus Infections; Female; HEK293 Cells; HeLa Cells; Humans; Immunogenicity, Vaccine; Injections, Intramuscular; Macaca fascicularis; Male; Mice; Mice, Inbred ICR; Nanoparticles; RNA, Messenger; RNA, Viral; Spike Glycoprotein, Coronavirus; Th1 Cells; Vaccine Potency; Vaccines, Synthetic; Vero Cells; Viral Vaccines","Zhang","Na-Na","State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China",NA
"235","32793504","10.3389/fonc.2020.01313","Urological Care and COVID-19: Looking Forward.","The recent COVID-19 pandemic represents a worldwide emergency and it is affecting healthcare at every level, including also urological care and especially oncologic patients. Recent epidemiological models show that, without effective treatment or vaccine, there will be a long-lasting phase of cohabitation with the virus. Current experts' opinions recommend performing only non-deferrable uro-oncological surgery and postponing other activities until the end of the emergency, with particular concer","2020","09","28","Front Oncol","Frontiers in oncology","COVID-19; management; organization; surgery; urology","Prayer-Galetti","Tommaso","Clinica Urologica, Department of Surgical and Oncological Sciences, University of Padua, Padua, Italy",NA
"236","32792466","10.1126/science.abe3147","A dangerous rush for vaccines.",NA,"2020","09","21","Science","Science (New York, N.Y.)","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Drug Approval; Humans; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Russia; United States; Viral Vaccines","Thorp","H Holden","H. Holden Thorp Editor-in-Chief, Science journals. hthorp@aaas","hthorp@aaas.org"
"237","32792417","10.1128/CMR.00072-20","Convalescent Plasma Therapy for COVID-19: State of the Art.","Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia. Recent large outbreaks of viral diseases for which effective antivirals or vaccines are still lacking has renewed the interest in CP as a life-saving treatment. The ongoing COVID-19 pandemic has led to the scaling up of CP therapy to unprecedented levels. Compared","2020","08","20","Clin Microbiol Rev","Clinical microbiology reviews","Ebola virus disease; Middle East respiratory syndrome; SARS; antibody-dependent enhancement; convalescent blood product; convalescent plasma; convalescent whole blood; coronavirus disease 2019; enzyme-linked immunosorbent assay; intravenous immunoglobulins; plaque reduction neutralization test; Antibodies, Neutralizing; Biological Specimen Banks; COVID-19; Coronavirus Infections; Donor Selection; Enzyme-Linked Immunosorbent Assay; Humans; Immunization, Passive; Neutralization Tests; Pandemics; Pneumonia, Viral; Severe Acute Respiratory Syndrome","Focosi","Daniele","North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy daniele.focosi@gmail","daniele.focosi@gmail.com"
"238","32792373","10.1126/science.369.6505.752","Antibodies may curb pandemic before vaccines.",NA,"2020","09","14","Science","Science (New York, N.Y.)","Antibodies, Monoclonal; Antibodies, Viral; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral","Cohen","Jon",NA,NA
"239","32792167","10.1016/j.bj.2020.07.008","Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19).","Coronavirus disease 2019 (COVID-19) is a major public health concern currently. To date, there are no approved antiviral drugs or vaccines against this transmissible disease. This report sheds light on available information for a better understanding of clinical trials and pharmacotherapy related to COVID-19. MEDLINE, PubMed, EMBASE, Scopus databases, Web of Science, WHO, and EU clinical trial sites were used to perform comparative analysis. Information was collected on the use of therapeutic ag","2020","12","29","Biomed J","Biomedical journal","COVID-19; Clinical trials; Corona pandemic; Therapeutic; Vaccination; COVID-19; Clinical Trials as Topic; Europe; Humans; SARS-CoV-2; World Health Organization","Verma","Henu Kumar","Institute of Experimental Endocrinology and Oncology CNR, Naples, Italy",NA
"240","32789505","10.1001/jama.2020.15543","Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.","A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed. To evaluate the safety and immunogenicity of an investigational inactivated whole-virus COVID-19 vaccine in China. In the phase 1 trial, 96 participants were assigned to 1 of the 3 dose groups (2.5, 5, and 10 ..g/dose) and an aluminum hydroxide (alum) adjuvant-only group (n...=...24 in each group), and received 3 intramuscular injections at days 0, 28, and 56. In the phase 2 trial, 224 adults were randomized to 5 ..g/dose ","2020","11","02","JAMA","JAMA","Adjuvants, Immunologic; Adolescent; Adult; Aluminum Hydroxide; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Dose-Response Relationship, Immunologic; Double-Blind Method; Female; Humans; Immunogenicity, Vaccine; Injections, Intramuscular; Male; Pandemics; Pneumonia, Viral; Propiolactone; SARS-CoV-2; Vaccines, Inactivated; Viral Vaccines; Young Adult","Xia","Shengli","Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China",NA
"241","32789501","10.1001/jama.2020.11244","Researchers Strive to Recruit Hard-Hit Minorities Into COVID-19 Vaccine Trials.",NA,"2020","09","29","JAMA","JAMA","African Americans; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Hispanic Americans; Humans; Minority Groups; Pandemics; Patient Selection; Pneumonia, Viral; SARS-CoV-2; United States; Viral Vaccines","Jaklevic","Mary Chris",NA,NA
"242","32789500","10.1001/jama.2020.15539","An Inactivated Virus Candidate Vaccine to Prevent COVID-19.",NA,"2020","10","29","JAMA","JAMA","Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Viral Vaccines","Mulligan","Mark J","NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York",NA
"243","32787752","10.2174/0929867327666200812215852","Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections.","Viral diseases are responsible for several deaths around the world. Over the past few years, the world has seen several outbreaks caused by viral diseases that for a long time seemed to possess no risk. These are diseases that have been forgotten for a long time and, until nowadays, there are no approved drugs or vaccines, leading the pharmaceutical industry and several research groups to run out of time in the search for new pharmacological treatments or prevention methods. In this context, dru","2020","08","13","Curr Med Chem","Current medicinal chemistry","Viral diseases; antiviral. ; drug design; drug repurposing; emerging viruses; molecular modeling","Dos Santos Nascimento","Igor Jos..","Chemistry and Biotechnology Institute, Federal University of Alagoas, Macei... Brazil",NA
"244","32785213","10.1038/s41586-020-2639-4","Phase..I/II study of COVID-19 RNA vaccine BNT162b1 in adults.","In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)<sup>1</sup>, a pandemic. With rapidly accumulating numbers of cases and deaths reported globally<sup>2</sup>, a vaccine is urgently needed. Here we report the available safety, tolerability and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT","2020","10","29","Nature","Nature","Adult; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Female; Humans; Immunization, Passive; Immunoglobulin G; Male; Middle Aged; Pandemics; Pneumonia, Viral; Spike Glycoprotein, Coronavirus; Time Factors; Viral Vaccines; Young Adult","Mulligan","Mark J","New York University Langone Vaccine Center, New York, NY, USA",NA
"245","32784685","10.3390/v12080861","Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?","Seven years after the Middle East respiratory syndrome (MERS) outbreak, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) made its first appearance in a food market in Wuhan, China, drawing an entirely new course to our lives. As the virus belongs to the same genus of MERS and SARS, researchers have been trying to draw lessons from previous outbreaks to find a potential cure. Although there were five Phase I human vaccine trials against SARS and MERS, the lack of data in humans ","2020","09","09","Viruses","Viruses","COVID-19; MERS; SARS; clinical trials; coronavirus; vaccine; Animals; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Middle East Respiratory Syndrome Coronavirus; Models, Animal; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; Vaccines, DNA; Viral Vaccines","Al-Kassmy","Jawad","Department of Experimental Surgery, McGill University, Montreal General Hospital 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada",NA
"246","32782402","10.1038/d41586-020-02360-y","Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?",NA,"2020","08","26","Nature","Nature","Infection; Medical research; Policy; SARS-CoV-2; Antibodies, Monoclonal; Antibodies, Neutralizing; Bioreactors; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Immunization, Passive; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Time Factors; Viral Vaccines","Ledford","Heidi",NA,NA
"247","32782400","10.1038/d41586-020-02386-2","Russia's fast-track coronavirus vaccine draws outrage over safety.",NA,"2020","08","26","Nature","Nature","SARS-CoV-2; Vaccines; Adenoviridae; Antibodies, Neutralizing; Antibodies, Viral; COVID-19 Vaccines; Clinical Protocols; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; Patient Safety; Quality Control; Russia; Spike Glycoprotein, Coronavirus; Time Factors; Uncertainty; Vaccination; Viral Vaccines","Callaway","Ewen",NA,NA
"248","32780300","10.1007/s40263-020-00756-y","Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.","The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic agent on the immune system is imperative during this special time. The infectious side-effect profile as well as the route and frequency of administration of each therapeutic agent s","2020","09","08","CNS Drugs","CNS drugs","Antirheumatic Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Immune System; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Risk Adjustment; SARS-CoV-2; Viral Vaccines","Zheng","Crystal","Raabe College of Pharmacy, Ohio Northern University, Ada, OH, USA",NA
"249","32778829","10.1038/s41577-020-00421-x","After 62 years of regulating immunity, dexamethasone meets COVID-19.",NA,"2020","10","06","Nat Rev Immunol","Nature reviews. Immunology","Alarmins; Anti-Inflammatory Agents; Betacoronavirus; COVID-19; Coronavirus Infections; Cytokine Release Syndrome; Dexamethasone; Drug Administration Schedule; Humans; Immunity, Innate; Immunosuppressive Agents; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Receptors, Glucocorticoid; SARS-CoV-2; Severity of Illness Index; Time Factors","Cain","Derek W","Department of Medicine, Duke Human Vaccine Institute, Duke University, Durham, NC, USA",NA
"250","32778225","10.1016/j.cell.2020.06.008","Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.","The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus maca","2020","08","28","Cell","Cell","BBIBP-CorV; SARS-CoV-2; inactivated vaccine; Animals; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Chlorocebus aethiops; Coronavirus Infections; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Guinea Pigs; Immunogenicity, Vaccine; Macaca fascicularis; Macaca mulatta; Male; Mice; Mice, Inbred BALB C; Pandemics; Phylogeny; Pneumonia, Viral; Rabbits; Rats; Rats, Wistar; SARS-CoV-2; Vaccines, Inactivated; Vero Cells; Viral Vaccines","Wang","Hui","Beijing Institute of Biological Products Company Limited, Beijing, China",NA
"251","32770854","10.1111/jpi.12683","Clinical trial to test the efficacy of melatonin in COVID-19.","The pharmacological properties of melatonin are well known. However, there is noticeable the lack of clinical trials that confirm the efficacy, security, absence of side effects in the short and long term, and the effective doses of melatonin. This point is especially important in diseases with high morbidity and mortality including COVID-19. There is not treatment for COVID-19, and several anti-inflammatory and antiviral molecules are being tested, and different vaccines are in preparation. Alt","2020","09","25","J Pineal Res","Journal of pineal research","COVID-19; SARS-CoV-2; clinical trial; intravenous melatonin; sepsis; Antioxidants; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Infusions, Intravenous; Melatonin; Pandemics; Pneumonia, Viral; SARS-CoV-2","Acu..a-Castroviejo","Dario","Faculty of Medicine, Department of Physiology, Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain",NA
"252","32769322","10.4103/IJPM.IJPM_779_20","COVID-19: An up-to-date review - from morphology to pathogenesis.","The entire world is under a devastating pandemic caused by COVID-19 with a high mortality rate. Knowledge of the viral structure, factors that help in its progression and spread, pathological findings, diagnostic methods and, treatment modalities helps in understanding the viral disease and also in treating the patients in a better way besides preventing the community spread of this deadly infection. The causative agent is a single- stranded RNA virus. The clinical spectrum varies in symptomatic","2020","08","17","Indian J Pathol Microbiol","Indian journal of pathology &amp; microbiology","COVID-19; RNA virus; pandemic; pathology; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; SARS-CoV-2","Bal","Amanjit","Department of Pathology, PGIMER, Chandigarh, India",NA
"253","32767687","10.1002/cbin.11440","Stem cell therapy for COVID-19: Possibilities and challenges.","Since its eruption in China, novel coronavirus disease (COVID-19) has been reported in most of the countries and territories (&gt;200) of the world with ...18 million confirmed cases (as of August 3, 2020). In most of the countries, COVID-19 upsurge is uncontrolled with a significant mortality rate. Currently, no treatment effective for COVID-19 is available in the form of vaccines or antiviral drugs and patients are currently treated symptomatically. Although the majority of the patients develo","2020","10","19","Cell Biol Int","Cell biology international","COVID-19; acellular therapy; coronavirus; mesenchymal stem cells; pandemic; stem cells; Animals; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Mesenchymal Stem Cell Transplantation; Pandemics; Pneumonia, Viral; SARS-CoV-2; Stem Cell Transplantation","Choudhery","Mahmood S","Tissue Engineering and Regenerative Medicine Laboratory, Department of Biomedical Sciences, King Edward Medical University, Lahore, Pakistan",NA
"254","32762250","10.1177/1945892420947929","Viral Infections of the Upper Airway in the Setting of COVID-19: A Primer for Rhinologists.","Viral respiratory tract infections are associated with a significant burden of disease and represent one of the leading causes of mortality worldwide. The current Coronavirus Disease 2019 (COVID-19) pandemic highlights the devastating toll that respiratory viruses have on humanity and the desperate need to understand the biological characteristics that define them in order to develop efficacious treatments and vaccines. To date, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has in","2020","12","29","Am J Rhinol Allergy","American journal of rhinology &amp; allergy","COVID-19; MERS-CoV; SARS-CoV; SARS-CoV-2; antivirals; coronavirus; otolaryngologists; respiratory infection; upper airway; viral; Anti-Infective Agents, Local; Antiviral Agents; COVID-19; Disease Transmission, Infectious; Humans; Otolaryngologists; Practice Guidelines as Topic; Respiratory Tract Diseases; SARS-CoV-2; Viral Vaccines; Viruses","Yuen","Erick","Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina",NA
"255","32758881","10.1016/j.mehy.2020.110039","SARS-CoV-2 and the sympathetic immune response: Dampening inflammation with antihypertensive drugs (Clonidine and Propranolol).","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a pandemic with the United States now carrying the highest number of cases and fatalities. Although vaccines and antiviral agents are the main focus of therapy, here we present a plausible hypothesis to leverage our understanding of neuroimmunomodulation to intervene in the pathophysiology of the disease to prevent death.","2021","01","05","Med Hypotheses","Medical hypotheses","Antihypertensive Agents; Antiviral Agents; COVID-19; Clonidine; Comorbidity; Disease Progression; Humans; Immune System; Inflammation; Interleukin-6; Models, Theoretical; Myocardium; Propranolol; Randomized Controlled Trials as Topic; Virus Replication","Hyoju","Sanjiv K","University of Chicago, Department of Surgery, Chicago, IL, United States. Electronic address: shyoju@surgery.bsd.uchicago","shyoju@surgery.bsd.uchicago.edu"
"256","32756549","10.1038/s41586-020-2622-0","SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.","A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity<sup>1</sup>. This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion co","2020","10","29","Nature","Nature","Animals; Antibodies, Neutralizing; Betacoronavirus; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Female; Lung; Mice; Mutation; Nose; Pandemics; Pneumonia, Viral; RNA, Messenger; RNA, Viral; SARS-CoV-2; Th1 Cells; Toll-Like Receptor 4; Viral Vaccines","Corbett","Kizzmekia S","Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA",NA
"257","32756480","10.3390/ijms21155559","COVID-19: The Immune Responses and Clinical Therapy Candidates.","The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US","2020","08","12","Int J Mol Sci","International journal of molecular sciences","COVID-19; MERS-CoV; SARS-CoV; SARS-CoV-2; adjunctive therapy; anti-parasite; anti-viral; clinical trial; immunotherapy; molecular immune response; Adaptive Immunity; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Immunotherapy; Middle East Respiratory Syndrome Coronavirus; Open Reading Frames; Pandemics; Pneumonia, Viral; SARS-CoV-2","Zhand","Sareh","School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia",NA
"258","32756371","10.3390/ijerph17155589","BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study.","Ecological studies have suggested fewer COVID-19 morbidities and mortalities in Bacillus Calmette-Gu..rin (BCG)-vaccinated countries than BCG-non-vaccinated countries. However, these studies obtained data during the early phase of the pandemic and did not adjust for potential confounders, including PCR-test numbers per population (PCR-tests). Currently-more than four months after declaration of the pandemic-the BCG-hypothesis needs reexamining. An ecological study was conducted by obtaining data","2020","08","21","Int J Environ Res Public Health","International journal of environmental research and public health","BCG; Bacillus Calmette...Gu..rin; COVID-19; SARS-CoV-2; coronavirus disease 2019; ecological study; morbidity; mortality; urbanization; vaccination; BCG Vaccine; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Middle Aged; Pandemics; Pneumonia, Viral; Research Design; SARS-CoV-2; Vaccination","Urashima","Mitsuyoshi","Division of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo 105-8461, Japan",NA
"259","32749496","10.1001/jama.2020.12461","The Development of COVID-19 Vaccines: Safeguards Needed.",NA,"2020","08","17","JAMA","JAMA","Adverse Drug Reaction Reporting Systems; Biomedical Research; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Informed Consent; Pandemics; Patient Safety; Pneumonia, Viral; United States; United States Food and Drug Administration; Viral Vaccines","Lurie","Nicole","Coalition for Epidemic Preparedness Innovations (CEPI), Harvard Medical School, Boston, Massachusetts",NA
"260","32746653","10.1080/17512433.2020.1805315","Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.","The coronavirus disease 2019 (COVID-19) pandemic has spread globally since it outbroke in December 2019. The urgent pandemic presents an unprecedented challenge to develop and identify effective medication therapy strategies to combat the COVID-19. Here, we summarized and evaluated the current treatment drugs and regimens, and put forward the treatment recommendations, including using the potential repurposed or experimental drugs against COVID-19, e.g. chloroquine (CQ), hydroxychloroquine (HCQ)","2020","11","06","Expert Rev Clin Pharmacol","Expert review of clinical pharmacology","COVID-19; Coronavirus disease; SARS-CoV-2; medication therapy; therapeutic strategies; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Global Health; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Yang","Xiaolei","School of Pharmacy, Fudan University , Shanghai, P.R. China",NA
"261","32742241","10.2139/ssrn.3639618","Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.","Biotin-labeled molecular probes, comprising specific regions of the SARS-CoV-2 spike, would be helpful in the isolation and characterization of antibodies targeting this recently emerged pathogen. To develop such probes, we designed constructs incorporating an N-terminal purification tag, a site-specific protease-cleavage site, the probe region of interest, and a C-terminal sequence targeted by biotin ligase. Probe regions included full-length spike ectodomain as well as various subregions, and ","2021","01","10","SSRN","SSRN","COVID-19; HRV3C protease; antibody; biotinylated probe; single-chain Fc; structurebased design","Zhou","Tongqing","Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA",NA
"262","32742146","10.18865/ed.30.3.429","Impact of COVID-19 on Clinical Research and Inclusion of Diverse Populations.","The randomized clinical trial (RCT) has long been recognized as the 'gold standard' for developing evidence for clinical treatments and vaccines; however, the successful implementation and translation of these findings is predicated upon external validity. The generalization of RCT findings are jeopardized by the lack of participation of at-risk groups such as African Americans, with long-recognized disproportional representation. Distinct factors that deter participation in RCTs include distrus","2020","08","13","Ethn Dis","Ethnicity &amp; disease","Clinical Research; Clinical Trials; External Validity; Underserved Minorities; African Americans; Betacoronavirus; COVID-19; Coronavirus Infections; Health Status Disparities; Humans; Male; Pandemics; Patient Participation; Patient Selection; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Socioeconomic Factors; Vulnerable Populations","Lackland","Daniel T","Division of Translational Neurosciences and Population Studies, Department of Neurology, Medical University of South Carolina, Charleston, SC",NA
"263","32741312","10.1080/07391102.2020.1801510","Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.","A new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide and become pandemic with thousands new deaths and infected cases globally. To treat the patients with coronavirus disease (COVID-19), currently no effective drug or vaccine is available. This necessity motivated us to explore potential lead compounds based natural products targeting main protease (M<sup>pro</sup>) enzyme of SARS-CoV-2. The M<sup>pro</sup> enzyme plays a key role in mediating viral re","2020","08","03","J Biomol Struct Dyn","Journal of biomolecular structure &amp; dynamics","ADMET; COVID 19; MD simulations; SARS-CoV-2; anthocyanin derivatives; docking workflow; main protease; pharmacophore modeling; virtual screening","Fakhar","Zeynab","Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa",NA
"264","32739342","10.1016/j.bcp.2020.114184","COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials.","COVID-19, the greatest public health emergency of the 21st century, has affected 215 countries and territories around the world resulting in 15,151,738 confirmed cases and 621,121 deaths. The outbreak has continued at breakneck pace despite stringent public health measures, ravaging the global economy and causing profound human casualties. Vaccination is currently the best bet for the prevention of COVID-19. Still, in its absence, there has been considerable interest in repurposing existing ther","2020","11","16","Biochem Pharmacol","Biochemical pharmacology","COVID-19; Clinical trials; Coronavirus; Drugs; SARS-CoV-2; Vaccines; Adjuvants, Pharmaceutic; Animals; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Repositioning; Humans; Immunization, Passive; Immunotherapy; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Chakraborty","Rohan","Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India",NA
"265","32737453","10.1038/d41586-020-02244-1","China's coronavirus vaccines are leaping ahead - but face challenges as virus wanes.",NA,"2020","09","03","Nature","Nature","Vaccines; Antibody-Dependent Enhancement; Betacoronavirus; Brazil; COVID-19; COVID-19 Vaccines; Child; China; Clinical Trials, Phase III as Topic; Coronavirus Infections; Drug Approval; Humans; Military Medicine; Pandemics; Patient Selection; Pneumonia, Viral; SARS-CoV-2; Time Factors; United Arab Emirates; Viral Vaccines","Cyranoski","David",NA,NA
